



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Lars BJÖRCK et al.

Title: METHOD FOR IDENTIFYING AN ANTI-STREPTOCOCCAL AGENT AND ITS USE FOR TREATING STREPTOCOCCAL INFECTIONS

Appl. No.: 10/553,904

Int'l Filing Date: 04/23/2004

371(c) Date: 03/29/2006

Examiner: Unassigned

Art Unit: Unassigned

Confirmation No. 7961

PETITION TO REVIVE UNAVOIDABLY ABANDONED APPLICATION
UNDER 37 C.F.R. § 1.137(a)

Mail Stop Petition
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This Petition is in reply to the Notice of Abandonment (Exhibit 1 to attached declaration of Howard N. Shipley) mailed November 30, 2006. Applicants' representative hereby petitions under 37 C.F.R. § 1.137(a) for withdrawal of the holding of abandonment and request that the response filed December 20, 2006 (Exhibit 2 to attached declaration of Howard N. Shipley) be entered and considered. The abandonment of the application was unavoidable.

The Petition is being filed within two months of the mailing date of the Notice of Abandonment.

01/31/2007 SZEWDIE1 00000039 10553904

01 FC:1452

500.00 0P

Applicants' respectfully request that this Petition to revive the application be granted for at least the following three reasons.

1. The application should not be considered abandoned. The PTO mailed a Notification of Defective Response (Exhibit 3 to attached declaration of Howard N. Shipley) on November 20, 2006. This Notice set a time limit of one month, or within the time remaining in the response set forth in the Notification to Comply with Sequence Requirements (referred as Notification of Missing Requirements) (Exhibit 4 to attached declaration of Howard N. Shipley) mailed April 27, 2006, whichever is longer. Applicants had until December 20, 2006 to respond to the Notification of Defective Response. Applicants filed a response to the Notice of Defective Response, on December 20, 2006. Therefore, all PTO requirements were complied with prior to expiration of the effective deadline of December 20, 2006.

2. The Notification of Missing Requirements was never received by Applicants' representative and possibly never mailed by the PTO. The entire delay in filing the required reply to the Notification of Missing Requirements from the due date of November 27, 2006 (the due date of April 27, 2006 including an additional 5 months permitted under 37 C.F.R. § 1.136(a)(1)) until the filing of this grantable petition under 37 C.F.R. § 1.137(a) was unavoidable. As shown in the attached Declaration, the Notification of Missing Requirements was never received by Applicants' representative and, thus, there was no possibility to avoid the abandonment of the application.

3. In the event that the PTO considers the Notice of Abandonment to be proper and also considers that the abandonment of the application was avoidable, the undersigned submits that the entire delay in filing the required reply from the due date for the reply until the filing of this grantable petition pursuant to 37 C.F.R. § 1.137(b) was unintentional. Applicants were not aware of the Notice of Missing Requirements and had no intention to abandon the application.

Applicants believe that the petition requirements of 37 § C.F.R. 1.137(a) are met, and respectfully urge that the abandonment be withdrawn and the application revived. If there are

any questions regarding this submission, the Patent Office is invited to contact the undersigned at the telephone number set forth below.

A credit card authorization form for the amount of \$500.00 is enclosed herewith. Should no proper payment be enclosed herewith, as by a check or credit card authorization form being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is hereby authorized to charge the unpaid amount, or any additional amount, to Deposit Account No. 19-0741. In addition, if abandonment of the application should be considered by the PTO to be unintentional (instead of unavoidable) the Commissioner is hereby authorized to charge any additional amount due, to Deposit Account No. 19-0741.

Respectfully submitted,

By 

Date January 30, 2007

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5300
Facsimile: (202) 672-5399

Howard N. Shipley
Attorney for Applicant
Registration No. 39,370



Atty. Dkt. No. 053694-0131

N THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Lars BJÖRCK et al.

Title: METHOD FOR IDENTIFYING AN ANTI-STREPTOCOCCAL AGENT AND ITS USE FOR TREATING STREPTOCOCCAL INFECTIONS

Appl. No.: 10/553,904

Int'l Filing Date: 04/23/2004

371(c) Date: 03/29/2006

Examiner: Unassigned

Art Unit: Unassigned

Confirmation No. 7961

DECLARATION OF HOWARD N. SHIPLEY

Mail Stop Petition
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The undersigned states the following:

1. I am a registered patent attorney of Foley & Lardner LLP. My registration number is 39,370.

2. Along with other attorneys at Foley & Lardner LLP (customer number 22428), I have been granted power of attorney to prosecute U.S. Patent Application Serial No. 10/553,904 ("the '904 application").

3. The correspondence address for the '904 application is:

22428
FOLEY & LARDNER LLP
Suite 500, 3000 K Street N.W.
Washington, D.C. 20007

4. Foley and Lardner LLP, through the undersigned, first became aware that a Notification of Missing Requirements (Exhibit 4) was mailed, when a Notification of Defective Response (Exhibit 3) mailed November 20, 2006 was received on November 27, 2006.

5. Thereafter, Foley and Lardner LLP received a Notice of Abandonment on December 1, 2006. The Notice of Abandonment recited that no response was filed to a Notification of Missing Requirements (Form PCT/DO/EO/905), mailed on April 27, 2006. However, Foley and Lardner LLP never received the Notification of Missing Requirements.

6. The application and docket records of Foley and Lardner LLP have been searched and there is no record that the Notification of Missing Requirements was ever received. A copy of the daily mail log showing all mail received from the U.S. Patent and Trademark Office from April 28, 2006 to May 12, 2006 is attached hereto as Exhibit 5. As can be seen from these records, no document of any type relating to the '904 application was received by Foley and Lardner LLP.

7. The Notification of Defective Response mailed November 20, 2006 established a one month time limit for response. A timely response was filed on December 20, 2006 completing all the PTO requirements for the application.

8. The PTO's records for the '904 application available on the USPTO PAIR Website, did not make reference to a Notification of Missing Requirements, and did not include a copy of the Notice. Copies of the various PAIR Website screens, printed on December 1 and 5, 2006, are attached hereto as Exhibit 6. According to the USPTO Website, the current status of the '904 application is "Application Undergoing Preexam Processing", as shown on the printout on January 29, 2007, attached as Exhibit 7.

Under penalty of perjury, the foregoing is true and correct.

Respectfully submitted,

Date 1/30/2007

By 

Howard N. Shipley
Attorney for Applicant
Registration No. 39,370



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.

10/553,904

FIRST NAMED APPLICANT

Lars Bjorck

ATTY. DOCKET NO.

053694-0131

INTERNATIONAL APPLICATION NO.

PCT/EP04/04429

I.A. FILING DATE

04/23/2004

PRIORITY DATE

04/23/2003

22428
 FOLEY AND LARDNER LLP
 SUITE 500
 3000 K STREET NW
 WASHINGTON, DC 20007

CONFIRMATION NO. 7961

371

ABANDONMENT/TERMINATION
 LETTER



OC000000021409312

Date Mailed: 11/30/2006

NOTIFICATION OF ABANDONMENT

The United States Patent and Trademark Office in its capacity as a Designated / Elected Office (37 CFR 1.495) has made the following determination:

- Applicant has failed to respond to the notification of MISSING REQUIREMENTS (Form PCT/DO/EO/905), mailed 04/27/2006 within the time period set therein.

Therefore, the above identified application failed to meet the requirements of 35 U.S.C. 371 and 37 CFR 1.495, and is ABANDONED AS TO THE UNITED STATES OF AMERICA.

PAULETTE R KIDWELL

Telephone: (703) 308-9140 EXT 216

PART 1 - ATTORNEY/APPLICANT COPY

FORM PCT/DO/EO/909 (371 Abandonment Notice)

THE U.S. PATENT AND TRADEMARK OFFICE OFFICIAL MAILROOM STAMP
AFFIXED HERETO ACKNOWLEDGED RECEIPT OF THE ITEMS CHECKED
BELOW:

Mailed Via Hand Delivery

H27510

Title: METHOD FOR IDENTIFYING AN ANTI-STREPTOCOCCAL AGENT AND ITS
USE FOR TREATING STREPTOCOCCAL INFECTIONS

Inventor(s): Lars BJÖRCK et al.


Appl. No.: 10/553,904

Dkt. No. 053694-0131




- Transmittal Letter to the US Designated/Elected Office – Subsequent Submission (2 pgs. IN DUPLICATE);
- Copy of Notification of Defective Response (3 pgs.);
- Response to Notification of Defective Response (2 pgs.);
- Statement to Support Filing and Submission of Sequence Listing (1 pg.);
- Computer Readable Format (CRF) of Sequence Listing (1 diskette);
- Paper Copy of Sequence Listing (20 pgs.);
- Preliminary Amendment (9 pgs.).

Due Date: December 20, 2006
Date Filed: December 20, 2006

Attorney Initials: MDKA
Insp. By: *[Signature]*



TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		ATTORNEY'S DOCKET NUMBER 053694-0131 U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) 10/553,904
INTERNATIONAL APPLICATION NO. PCT/EP2004/004429	INTERNATIONAL FILING DATE 4/23/2004	PRIORITY DATE CLAIMED 4/23/2003
TITLE OF INVENTION METHOD FOR IDENTIFYING AN ANTI-STREPTOCOCCAL AGENT AND ITS USE FOR TREATING STREPTOCOCCAL INFECTIONS		
APPLICANT(S) FOR DO/EO/US Lars BJÖRCK et al.		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
1. <input type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input checked="" type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. <input type="checkbox"/> The US has been elected (Article 31). 5. <input type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). <input type="checkbox"/> has been communicated by the International Bureau. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US) 6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <input type="checkbox"/> is attached hereto. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <input type="checkbox"/> are attached hereto (required only if not transmitted by the International Bureau). <input type="checkbox"/> have been communicated by the International Bureau. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input type="checkbox"/> A Substitute Declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).		
Items 11 to 20 below concern other document(s) or information included:		
11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A preliminary amendment. 14. <input type="checkbox"/> A Supplemental Application Data Sheet under 37 CFR 1.76. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A power of attorney and/or change of address letter. 17. <input checked="" type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 – 1.825 18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). 19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 20. <input checked="" type="checkbox"/> Other items or information: Sequence Statement to Support Filing and Submission with paper copy (20 pgs.) of Sequence Listing; Letter RE: Notification of Defective Response		

U.S. APPLICATION NO. (If known, see 37 CFR. 1.5) 10/553,904		INTERNATIONAL APPLICATION NO. PCT/EP2004/004429	ATTORNEY'S DOCKET NUMBER 053694-0131																																																																																																																																																														
<p>The following fees have been submitted:</p> <table border="1"> <tr> <td>21. <input type="checkbox"/> Basic national fee</td> <td>\$300</td> <td>\$ 0.00</td> <td></td> </tr> <tr> <td>22. <input type="checkbox"/> Examination fee</td> <td></td> <td></td> <td></td> </tr> <tr> <td colspan="2">If International preliminary examination report prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4)</td> <td>\$100</td> <td>\$ 0.00</td> </tr> <tr> <td colspan="2">All other situations</td> <td>\$200</td> <td></td> </tr> <tr> <td>23. <input type="checkbox"/> Search fee</td> <td></td> <td></td> <td></td> </tr> <tr> <td colspan="2">Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority</td> <td>\$100</td> <td></td> </tr> <tr> <td colspan="2">International Search Report prepared and provided to the Office</td> <td>\$400</td> <td></td> </tr> <tr> <td colspan="2">All other situations</td> <td>\$500</td> <td>\$ 0.00</td> </tr> <tr> <td colspan="4">TOTAL OF ABOVE 21, 22 and 23 =</td> <td>\$ 0.00</td> </tr> <tr> <td colspan="5"> <input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$ for each additional 50 sheets of paper or fraction thereof. </td> </tr> <tr> <td>Total Sheets</td> <td>Extra sheets</td> <td>Number of each additional 50 or fraction thereof (round up to a whole number)</td> <td>RATE</td> <td></td> </tr> <tr> <td>65 - 100 = 0</td> <td>/50 = 0</td> <td></td> <td>x \$250.00</td> <td>\$ 0.00</td> </tr> <tr> <td colspan="5">Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e))</td> </tr> <tr> <td>CLAIMS</td> <td>NUMBER FILED</td> <td>NUMBER EXTRA</td> <td>RATE</td> <td>\$</td> </tr> <tr> <td>Total Claims</td> <td>19 - 20 = 0</td> <td></td> <td>x \$ 50.00</td> <td>\$ 0.00</td> </tr> <tr> <td>Independent Claims</td> <td>2 - 3 = 0</td> <td></td> <td>x \$ 200.00</td> <td>\$ 0.00</td> </tr> <tr> <td colspan="2">MULTIPLE DEPENDENT CLAIM(S) (if applicable)</td> <td></td> <td>+ \$ 360.00</td> <td>\$</td> </tr> <tr> <td colspan="4">TOTAL OF ABOVE CALCULATIONS =</td> <td>\$ 0.00</td> </tr> <tr> <td colspan="4"> <input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by ½. </td> <td>\$ 0.00</td> </tr> <tr> <td colspan="5">SUBTOTAL = \$ 0.00</td> </tr> <tr> <td colspan="5">Processing fee of 130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).</td> </tr> <tr> <td colspan="4">TOTAL NATIONAL FEE =</td> <td>\$ 0.00</td> </tr> <tr> <td colspan="5">Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). 40.00 per property</td> </tr> <tr> <td colspan="4">TOTAL FEES ENCLOSED =</td> <td>\$ 0.00</td> </tr> <tr> <td colspan="4"></td> <td>Amount to be refunded: charged:</td> </tr> <tr> <td>a. <input type="checkbox"/> A check in the amount of \$ 0.00 to cover the above fees is enclosed.</td> <td colspan="4"></td> </tr> <tr> <td>b. <input type="checkbox"/> Please charge my Deposit Account No. <u>19-0741</u> in the amount of \$ 0.00 to cover the above fees. A duplicate copy of this sheet is enclosed.</td> <td colspan="4"></td> </tr> <tr> <td>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>19-0741</u>. A duplicate copy of this sheet is enclosed.</td> <td colspan="4"></td> </tr> <tr> <td>d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</td> <td colspan="4"></td> </tr> <tr> <td colspan="5"> NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status. </td> </tr> <tr> <td colspan="5">SEND ALL CORRESPONDENCE TO:</td> </tr> <tr> <td colspan="5"> Foley & Lardner LLP Customer Number: 22428 </td> </tr> <tr> <td colspan="5">  SIGNATURE Michael D. Kaminski NAME 32,904 REGISTRATION NUMBER </td> </tr> </table>					21. <input type="checkbox"/> Basic national fee	\$300	\$ 0.00		22. <input type="checkbox"/> Examination fee				If International preliminary examination report prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4)		\$100	\$ 0.00	All other situations		\$200		23. <input type="checkbox"/> Search fee				Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority		\$100		International Search Report prepared and provided to the Office		\$400		All other situations		\$500	\$ 0.00	TOTAL OF ABOVE 21, 22 and 23 =				\$ 0.00	<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$ for each additional 50 sheets of paper or fraction thereof.					Total Sheets	Extra sheets	Number of each additional 50 or fraction thereof (round up to a whole number)	RATE		65 - 100 = 0	/50 = 0		x \$250.00	\$ 0.00	Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e))					CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	Total Claims	19 - 20 = 0		x \$ 50.00	\$ 0.00	Independent Claims	2 - 3 = 0		x \$ 200.00	\$ 0.00	MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$ 360.00	\$	TOTAL OF ABOVE CALCULATIONS =				\$ 0.00	<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by ½.				\$ 0.00	SUBTOTAL = \$ 0.00					Processing fee of 130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).					TOTAL NATIONAL FEE =				\$ 0.00	Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). 40.00 per property					TOTAL FEES ENCLOSED =				\$ 0.00					Amount to be refunded: charged:	a. <input type="checkbox"/> A check in the amount of \$ 0.00 to cover the above fees is enclosed.					b. <input type="checkbox"/> Please charge my Deposit Account No. <u>19-0741</u> in the amount of \$ 0.00 to cover the above fees. A duplicate copy of this sheet is enclosed.					c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>19-0741</u> . A duplicate copy of this sheet is enclosed.					d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.					NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.					SEND ALL CORRESPONDENCE TO:					Foley & Lardner LLP Customer Number: 22428					 SIGNATURE Michael D. Kaminski NAME 32,904 REGISTRATION NUMBER				
21. <input type="checkbox"/> Basic national fee	\$300	\$ 0.00																																																																																																																																																															
22. <input type="checkbox"/> Examination fee																																																																																																																																																																	
If International preliminary examination report prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4)		\$100	\$ 0.00																																																																																																																																																														
All other situations		\$200																																																																																																																																																															
23. <input type="checkbox"/> Search fee																																																																																																																																																																	
Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority		\$100																																																																																																																																																															
International Search Report prepared and provided to the Office		\$400																																																																																																																																																															
All other situations		\$500	\$ 0.00																																																																																																																																																														
TOTAL OF ABOVE 21, 22 and 23 =				\$ 0.00																																																																																																																																																													
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$ for each additional 50 sheets of paper or fraction thereof.																																																																																																																																																																	
Total Sheets	Extra sheets	Number of each additional 50 or fraction thereof (round up to a whole number)	RATE																																																																																																																																																														
65 - 100 = 0	/50 = 0		x \$250.00	\$ 0.00																																																																																																																																																													
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e))																																																																																																																																																																	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$																																																																																																																																																													
Total Claims	19 - 20 = 0		x \$ 50.00	\$ 0.00																																																																																																																																																													
Independent Claims	2 - 3 = 0		x \$ 200.00	\$ 0.00																																																																																																																																																													
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$ 360.00	\$																																																																																																																																																													
TOTAL OF ABOVE CALCULATIONS =				\$ 0.00																																																																																																																																																													
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by ½.				\$ 0.00																																																																																																																																																													
SUBTOTAL = \$ 0.00																																																																																																																																																																	
Processing fee of 130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).																																																																																																																																																																	
TOTAL NATIONAL FEE =				\$ 0.00																																																																																																																																																													
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). 40.00 per property																																																																																																																																																																	
TOTAL FEES ENCLOSED =				\$ 0.00																																																																																																																																																													
				Amount to be refunded: charged:																																																																																																																																																													
a. <input type="checkbox"/> A check in the amount of \$ 0.00 to cover the above fees is enclosed.																																																																																																																																																																	
b. <input type="checkbox"/> Please charge my Deposit Account No. <u>19-0741</u> in the amount of \$ 0.00 to cover the above fees. A duplicate copy of this sheet is enclosed.																																																																																																																																																																	
c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>19-0741</u> . A duplicate copy of this sheet is enclosed.																																																																																																																																																																	
d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.																																																																																																																																																																	
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.																																																																																																																																																																	
SEND ALL CORRESPONDENCE TO:																																																																																																																																																																	
Foley & Lardner LLP Customer Number: 22428																																																																																																																																																																	
 SIGNATURE Michael D. Kaminski NAME 32,904 REGISTRATION NUMBER																																																																																																																																																																	

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		ATTORNEY'S DOCKET NUMBER 053694-0131 U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) 10/553,904
INTERNATIONAL APPLICATION NO. PCT/EP2004/004429	INTERNATIONAL FILING DATE 4/23/2004	PRIORITY DATE CLAIMED 4/23/2003
TITLE OF INVENTION METHOD FOR IDENTIFYING AN ANTI-STREPTOCOCCAL AGENT AND ITS USE FOR TREATING STREPTOCOCCAL INFECTIONS		
APPLICANT(S) FOR DO/EO/US Lars BJÖRCK et al.		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
1. <input type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input checked="" type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. <input type="checkbox"/> The US has been elected (Article 31). 5. <input type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). <input type="checkbox"/> has been communicated by the International Bureau. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US) 6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <input type="checkbox"/> is attached hereto. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <input type="checkbox"/> are attached hereto (required only if not transmitted by the International Bureau). <input type="checkbox"/> have been communicated by the International Bureau. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input type="checkbox"/> A Substitute Declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).		
Items 11 to 20 below concern other document(s) or information included:		
11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A preliminary amendment. 14. <input type="checkbox"/> A Supplemental Application Data Sheet under 37 CFR 1.76. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A power of attorney and/or change of address letter. 17. <input checked="" type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 – 1.825 18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). 19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 20. <input checked="" type="checkbox"/> Other items or information: Sequence Statement to Support Filing and Submission with paper copy (20 pgs.) of Sequence Listing; Letter RE: Notification of Defective Response		

U.S. APPLICATION NO. (If known, see 37 CFR. 1.5) 10/553,904	INTERNATIONAL APPLICATION NO. PCT/EP2004/004429	ATTORNEY'S DOCKET NUMBER 053694-0131				
The following fees have been submitted:						
21. <input type="checkbox"/> Basic national fee \$300		\$ 0.00				
22. <input type="checkbox"/> Examination fee If International preliminary examination report prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4) All other situations \$100 \$200		\$ 0.00				
23. <input type="checkbox"/> Search fee Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority \$100 International Search Report prepared and provided to the Office \$400 All other situations \$500		\$ 0.00				
TOTAL OF ABOVE 21, 22 and 23 =		\$ 0.00				
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$ for each additional 50 sheets of paper or fraction thereof.						
Total Sheets	Extra sheets	Number of each additional 50 or fraction thereof (round up to a whole number)				
65 - 100 = 0	/50 = 0	x \$250.00				
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e))						
CLAIMS	NUMBER FILED	NUMBER EXTRA				
Total Claims	19 - 20 = 0	x \$ 50.00				
Independent Claims	2 - 3 = 0	x \$ 200.00				
MULTIPLE DEPENDENT CLAIM(S) (if applicable)		+ \$ 360.00				
TOTAL OF ABOVE CALCULATIONS =		\$ 0.00				
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by ½.		+ \$ 0.00				
SUBTOTAL = \$ 0.00						
Processing fee of 130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).						
TOTAL NATIONAL FEE = \$ 0.00						
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). 40.00 per property						
TOTAL FEES ENCLOSED = \$ 0.00						
<table border="1"> <tr> <td>Amount to be refunded:</td> <td></td> </tr> <tr> <td>charged:</td> <td></td> </tr> </table>			Amount to be refunded:		charged:	
Amount to be refunded:						
charged:						
a. <input type="checkbox"/> A check in the amount of \$ 0.00 to cover the above fees is enclosed.						
b. <input type="checkbox"/> Please charge my Deposit Account No. <u>19-0741</u> in the amount of \$ 0.00 to cover the above fees. A duplicate copy of this sheet is enclosed.						
c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>19-0741</u> . A duplicate copy of this sheet is enclosed.						
d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.						
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.						
SEND ALL CORRESPONDENCE TO:						
<u>Foley & Lardner LLP</u> Customer Number: 22428						
<u>Michael D. Kaminski</u> SIGNATURE <u>Michael D. Kaminski</u> NAME <u>32,904</u> REGISTRATION NUMBER						

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Lars BJÖRCK et al.

Title: METHOD FOR IDENTIFYING AN ANTI-STREPTOCOCCAL AGENT AND ITS USE FOR TREATING STREPTOCOCCAL INFECTIONS

Appl. No.: 10/553,904

International Filing Date: 04/23/2004

371(c) Date: 03/29/2006

Examiner: Unassigned

Art Unit: Unassigned

Confirmation Number:

7961

RESPONSE TO NOTIFICATION OF DEFECTIVE RESPONSE

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Notification of Defective Response mailed November 20, 2006, in the above-identified application, transmitted herewith are the following documents:

Enclosed are:

- [X] Return Copy of Notification of Defective Response (2 pgs.)
- [X] Statement to Support Filing and Submission in Accordance with 37 C.F.R. §§1.821-1.825 (1 pg.)
- [X] Computer Readable Format (CRF) and Paper Copy of Sequence Listing (20 pgs.)

[X] Preliminary Amendment (9 pgs.)

The undersigned is in receipt of a Notice of Abandonment, mailed November 30, 2006, which we believe has been issued in error. The Notification of Defective Response mailed November 20, 2006 provided Applicants 30 days to respond. Applicants request that the attached timely response be entered and a formal Notification of Acceptance of filing under 35 USC 371 be issued in this application.

Although Applicant believes that no fee is required for this Request, the Commissioner is hereby authorized to charge any additional fees which may be required for this Request to Deposit Account No. 19-0741.

Respectfully submitted,

Date December 20, 2006

By Michael D. Kaminski

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5490
Facsimile: (202) 672-5399

Michael D. Kaminski
Attorney for Applicant
Registration No. 32,904

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket No: 053694-0131

In re patent application of

BJORCK, LARS et al.

Serial No. 10/553,904

Filed: October 21, 2005

For: METHOD FOR IDENTIFYING AN ANTI-STREPTOCOCCAL AGENT AND ITS USE FOR
TREATING STREPTOCOCCAL INFECTIONS

STATEMENT TO SUPPORT FILING AND SUBMISSION IN
ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
Mail Stop SEQUENCE

Sir:

In connection with a Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

1. the submission, filed herewith in accordance with 37 C.F.R. § 1.821(g), does not include new matter;

2. the content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same.

Respectfully submitted,

Dec. 14, 2006
Date

James A. Coburn

HARBOR CONSULTING IP SERVICES, INC.
1500A Lafayette Road, #262
Portsmouth, N.H. 03801
800-318-3021

COMPUTER READABLE FORMAT (CRF)
OF SEQUENCE LISTING

DOCKET NO: 053694-0131
Inventor: Lars BJÖRCK et al.
Title: METHOD FOR IDENTIFYING AN ...
Appln. No.: 10/553,904
Filing Date: 03/29/2006

RECORDED ON 12/14/2006
PC/MS-DOS PATENTIN 3.3

SEQUENCE LISTING

<110> BJORCK, LARS
HERWALD, HEIKO
MORGELIN, MATTHIAS
RUSSELL, WAYNE
NORRBY-TEGLUND, ANNA
LINDBOM, LENNART
SOLLENBERG, ULLA
CRAMER, HENNING
FLODGAARD, HANS

<120> METHOD FOR IDENTIFYING AN ANTI-STREPTOCOCCAL AGENT AND
ITS USE FOR TREATING STREPTOCOCCAL INFECTIONS

<130> 053694-0131

<140> 10/553,904
<141> 2005-10-21

<150> PCT/EP04/004429
<151> 2004-04-23

<150> GB 0309246.7
<151> 2003-04-23

<150> GB 0329112.7
<151> 2003-12-16

<160> 11

<170> PatentIn Ver. 3.3

<210> 1
<211> 484
<212> PRT
<213> Streptococcus pyogenes

<400> 1
Met Ala Lys Asn Asn Thr Asn Arg His Tyr Ser Leu Arg Lys Leu Lys
1 5 10 15
Thr Gly Thr Ala Ser Val Ala Val Ala Leu Thr Val Leu Gly Ala Gly
20 25 30
Phe Ala Asn Gln Thr Glu Val Lys Ala Asn Gly Asp Gly Asn Pro Arg
35 40 45
Glu Val Ile Glu Asp Leu Ala Ala Asn Asn Pro Ala Ile Gln Asn Ile
50 55 60
Arg Leu Arg Tyr Glu Asn Lys Asp Leu Lys Ala Arg Leu Glu Asn Ala
65 70 75 80
Met Glu Val Ala Gly Arg Asp Phe Lys Arg Ala Glu Glu Leu Glu Lys
85 90 95

Ala Lys Gln Ala Leu Glu Asp Gln Arg Lys Asp Leu Glu Thr Lys Leu
 100 105 110

Lys Glu Leu Gln Gln Asp Tyr Asp Leu Ala Lys Glu Ser Thr Ser Trp
 115 120 125

Asp Arg Gln Arg Leu Glu Lys Glu Leu Glu Glu Lys Lys Glu Ala Leu
 130 135 140

Glu Leu Ala Ile Asp Gln Ala Ser Arg Asp Tyr His Arg Ala Thr Ala
 145 150 155 160

Leu Glu Lys Glu Leu Glu Glu Lys Lys Ala Leu Glu Leu Ala Ile
 165 170 175

Asp Gln Ala Ser Gln Asp Tyr Asn Arg Ala Asn Val Leu Glu Lys Glu
 180 185 190

Leu Glu Thr Ile Thr Arg Glu Gln Glu Ile Asn Arg Asn Leu Leu Gly
 195 200 205

Asn Ala Lys Leu Glu Leu Asp Gln Leu Ser Ser Glu Lys Glu Gln Leu
 210 215 220

Thr Ile Glu Lys Ala Lys Leu Glu Glu Lys Gln Ile Ser Asp Ala
 225 230 235 240

Ser Arg Gln Ser Leu Arg Arg Asp Leu Asp Ala Ser Arg Glu Ala Lys
 245 250 255

Lys Gln Val Glu Lys Asp Leu Ala Asn Leu Thr Ala Glu Leu Asp Lys
 260 265 270

Val Lys Glu Asp Lys Gln Ile Ser Asp Ala Ser Arg Gln Gly Leu Arg
 275 280 285

Arg Asp Leu Asp Ala Ser Arg Glu Ala Lys Lys Gln Val Glu Lys Asp
 290 295 300

Leu Ala Asn Leu Thr Ala Glu Leu Asp Lys Val Lys Glu Glu Lys Gln
 305 310 315 320

Ile Ser Asp Ala Ser Arg Gln Gly Leu Arg Arg Asp Leu Asp Ala Ser
 325 330 335

Arg Glu Ala Lys Lys Gln Val Glu Lys Ala Leu Glu Glu Ala Asn Ser
 340 345 350

Lys Leu Ala Ala Leu Glu Lys Leu Asn Lys Glu Leu Glu Glu Ser Lys
 355 360 365

Lys Leu Thr Glu Lys Glu Lys Ala Glu Leu Gln Ala Lys Leu Glu Ala
 370 375 380

Glu Ala Lys Ala Leu Lys Glu Gln Leu Ala Lys Gln Ala Glu Glu Leu
 385 390 395 400

Ala Lys Leu Arg Ala Gly Lys Ala Ser Asp Ser Gln Thr Pro Asp Thr
 405 410 415

Lys Pro Gly Asn Lys Ala Val Pro Gly Lys Gly Gln Ala Pro Gln Ala
 420 425 430

Gly Thr Lys Pro Asn Gln Asn Lys Ala Pro Met Lys Glu Thr Lys Arg
 435 440 445

Gln Leu Pro Ser Thr Gly Glu Thr Ala Asn Pro Phe Phe Thr Ala Ala
 450 455 460

Ala Leu Thr Val Met Ala Thr Ala Gly Val Ala Ala Val Val Lys Arg
 465 470 475 480

Lys Glu Glu Asn

<210> 2

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 2

Gly Pro Arg Pro
 1

<210> 3

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 3

Gly His Arg Pro
 1

<210> 4

<211> 13

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic primer

<400> 4

gggttgttga gaa

Gly Ser Thr Ser Tyr Gly Thr Gly Ser Glu Thr Glu Ser Pro Arg Asn
 275 280 285
 Pro Ser Ser Ala Gly Ser Trp Asn Ser Gly Ser Ser Gly Pro Gly Ser
 290 295 300
 Thr Gly Asn Arg Asn Pro Gly Ser Ser Gly Thr Gly Gly Thr Ala Thr
 305 310 315 320
 Trp Lys Pro Gly Ser Ser Gly Pro Gly Ser Thr Gly Ser Trp Asn Ser
 325 330 335
 Gly Ser Ser Gly Thr Gly Ser Thr Gly Asn Gln Asn Pro Gly Ser Pro
 340 345 350
 Arg Pro Gly Ser Thr Gly Thr Trp Asn Pro Gly Ser Ser Glu Arg Gly
 355 360 365
 Ser Ala Gly His Trp Thr Ser Glu Ser Ser Val Ser Gly Ser Thr Gly
 370 375 380
 Gln Trp His Ser Glu Ser Gly Ser Phe Arg Pro Asp Ser Pro Gly Ser
 385 390 395 400
 Gly Asn Ala Arg Pro Asn Asn Pro Asp Trp Gly Thr Phe Glu Glu Val
 405 410 415
 Ser Gly Asn Val Ser Pro Gly Thr Arg Arg Glu Tyr His Thr Glu Lys
 420 425 430
 Leu Val Thr Ser Lys Gly Asp Lys Glu Leu Arg Thr Gly Lys Glu Lys
 435 440 445
 Val Thr Ser Gly Ser Thr Thr Thr Arg Arg Ser Cys Ser Lys Thr
 450 455 460
 Val Thr Lys Thr Val Ile Gly Pro Asp Gly His Lys Glu Val Thr Lys
 465 470 475 480
 Glu Val Val Thr Ser Glu Asp Gly Ser Asp Cys Pro Glu Ala Met Asp
 485 490 495
 Leu Gly Thr Leu Ser Gly Ile Gly Thr Leu Asp Gly Phe Arg His Arg
 500 505 510
 His Pro Asp Glu Ala Ala Phe Phe Asp Thr Ala Ser Thr Gly Lys Thr
 515 520 525
 Phe Pro Gly Phe Phe Ser Pro Met Leu Gly Glu Phe Val Ser Glu Thr
 530 535 540
 Glu Ser Arg Gly Ser Glu Ser Gly Ile Phe Thr Asn Thr Lys Glu Ser
 545 550 555 560
 Ser Ser His His Pro Gly Ile Ala Glu Phe Pro Ser Arg Gly Lys Ser
 565 570 575

Ser Ser Tyr Ser Lys Gln Phe Thr Ser Ser Thr Ser Tyr Asn Arg Gly
 580 585 590

Asp Ser Thr Phe Glu Ser Lys Ser Tyr Lys Met Ala Asp Glu Ala Gly
 595 600 605

Ser Glu Ala Asp His Glu Gly Thr His Ser Thr Lys Arg Gly His Ala
 610 615 620

Lys Ser Arg Pro Val Arg Gly Ile His Thr Ser Pro Leu Gly Lys Pro
 625 630 635 640

Ser Leu Ser Pro

<210> 6

<211> 491

<212> PRT

<213> Homo sapiens

<400> 6

Met Lys Arg Met Val Ser Trp Ser Phe His Lys Leu Lys Thr Met Lys
 1 5 10 15

His Leu Leu Leu Leu Leu Cys Val Phe Leu Val Lys Ser Gln Gly
 20 25 30

Val Asn Asp Asn Glu Glu Gly Phe Phe Ser Ala Arg Gly His Arg Pro
 35 40 45

Leu Asp Lys Lys Arg Glu Glu Ala Pro Ser Leu Arg Pro Ala Pro Pro
 50 55 60

Pro Ile Ser Gly Gly Tyr Arg Ala Arg Pro Ala Lys Ala Ala Ala
 65 70 75 80

Thr Gln Lys Lys Val Glu Arg Lys Ala Pro Asp Ala Gly Gly Cys Leu
 85 90 95

His Ala Asp Pro Asp Leu Gly Val Leu Cys Pro Thr Gly Cys Gln Leu
 100 105 110

Gln Glu Ala Leu Leu Gln Gln Glu Arg Pro Ile Arg Asn Ser Val Asp
 115 120 125

Glu Leu Asn Asn Asn Val Glu Ala Val Ser Gln Thr Ser Ser Ser Ser
 130 135 140

Phe Gln Tyr Met Tyr Leu Leu Lys Asp Leu Trp Gln Lys Arg Gln Lys
 145 150 155 160

Gln Val Lys Asp Asn Glu Asn Val Val Asn Glu Tyr Ser Ser Glu Leu
 165 170 175

Glu Lys His Gln Leu Tyr Ile Asp Glu Thr Val Asn Ser Asn Ile Pro
 180 185 190

Thr Asn Leu Arg Val Leu Arg Ser Ile Leu Glu Asn Leu Arg Ser Lys
 195 200 205

Ile Gln Lys Leu Glu Ser Asp Val Ser Ala Gln Met Glu Tyr Cys Arg
 210 215 220

Thr Pro Cys Thr Val Ser Cys Asn Ile Pro Val Val Ser Gly Lys Glu
 225 230 235 240

Cys Glu Glu Ile Ile Arg Lys Gly Gly Glu Thr Ser Glu Met Tyr Leu
 245 250 255

Ile Gln Pro Asp Ser Ser Val Lys Pro Tyr Arg Val Tyr Cys Asp Met
 260 265 270

Asn Thr Glu Asn Gly Gly Trp Thr Val Ile Gln Asn Arg Gln Asp Gly
 275 280 285

Ser Val Asp Phe Gly Arg Lys Trp Asp Pro Tyr Lys Gln Gly Phe Gly
 290 295 300

Asn Val Ala Thr Asn Thr Asp Gly Lys Asn Tyr Cys Gly Leu Pro Gly
 305 310 315 320

Glu Tyr Trp Leu Gly Asn Asp Lys Ile Ser Gln Leu Thr Arg Met Gly
 325 330 335

Pro Thr Glu Leu Leu Ile Glu Met Glu Asp Trp Lys Gly Asp Lys Val
 340 345 350

Lys Ala His Tyr Gly Gly Phe Thr Val Gln Asn Glu Ala Asn Lys Tyr
 355 360 365

Gln Ile Ser Val Asn Lys Tyr Arg Gly Thr Ala Gly Asn Ala Leu Met
 370 375 380

Asp Gly Ala Ser Gln Leu Met Gly Glu Asn Arg Thr Met Thr Ile His
 385 390 395 400

Asn Gly Met Phe Phe Ser Thr Tyr Asp Arg Asp Asn Asp Gly Trp Leu
 405 410 415

Thr Ser Asp Pro Arg Lys Gln Cys Ser Lys Glu Asp Gly Gly Trp
 420 425 430

Trp Tyr Asn Arg Cys His Ala Ala Asn Pro Asn Gly Arg Tyr Tyr Trp
 435 440 445

Gly Gly Gln Tyr Thr Trp Asp Met Ala Lys His Gly Thr Asp Asp Gly
 450 455 460

Val Val Trp Met Asn Trp Lys Gly Ser Trp Tyr Ser Met Arg Lys Met
 465 470 475 480

Ser Met Lys Ile Arg Pro Phe Phe Pro Gln Gln
 485 490

<210> 7
<211> 453
<212> PRT
<213> Homo sapiens

<400> 7
Met Ser Trp Ser Leu His Pro Arg Asn Leu Ile Leu Tyr Phe Tyr Ala
1 5 10 15
Leu Leu Phe Leu Ser Ser Thr Cys Val Ala Tyr Val Ala Thr Arg Asp
20 25 30
Asn Cys Cys Ile Leu Asp Glu Arg Phe Gly Ser Tyr Cys Pro Thr Thr
35 40 45
Cys Gly Ile Ala Asp Phe Leu Ser Thr Tyr Gln Thr Lys Val Asp Lys
50 55 60
Asp Leu Gln Ser Leu Glu Asp Ile Leu His Gln Val Glu Asn Lys Thr
65 70 75 80
Ser Glu Val Lys Gln Leu Ile Lys Ala Ile Gln Leu Thr Tyr Asn Pro
85 90 95
Asp Glu Ser Ser Lys Pro Asn Met Ile Asp Ala Ala Thr Leu Lys Ser
100 105 110
Arg Ile Met Leu Glu Glu Ile Met Lys Tyr Glu Ala Ser Ile Leu Thr
115 120 125
His Asp Ser Ser Ile Arg Tyr Leu Gln Glu Ile Tyr Asn Ser Asn Asn
130 135 140
Gln Lys Ile Val Asn Leu Lys Glu Lys Val Ala Gln Leu Glu Ala Gln
145 150 155 160
Cys Gln Glu Pro Cys Lys Asp Thr Val Gln Ile His Asp Ile Thr Gly
165 170 175
Lys Asp Cys Gln Asp Ile Ala Asn Lys Gly Ala Lys Gln Ser Gly Leu
180 185 190
Tyr Phe Ile Lys Pro Leu Lys Ala Asn Gln Gln Phe Leu Val Tyr Cys
195 200 205
Glu Ile Asp Gly Ser Gly Asn Gly Trp Thr Val Phe Gln Lys Arg Leu
210 215 220
Asp Gly Ser Val Asp Phe Lys Lys Asn Trp Ile Gln Tyr Lys Glu Gly
225 230 235 240
Phe Gly His Leu Ser Pro Thr Gly Thr Thr Glu Phe Trp Leu Gly Asn
245 250 255
Glu Lys Ile His Leu Ile Ser Thr Gln Ser Ala Ile Pro Tyr Ala Leu
260 265 270

Arg Val Glu Leu Glu Asp Trp Asn Gly Arg Thr Ser Thr Ala Asp Tyr
 275 280 285
 Ala Met Phe Lys Val Gly Pro Glu Ala Asp Lys Tyr Arg Leu Thr Tyr
 290 295 300
 Ala Tyr Phe Ala Gly Gly Asp Ala Gly Asp Ala Phe Asp Gly Phe Asp
 305 310 315 320
 Phe Gly Asp Asp Pro Ser Asp Lys Phe Phe Thr Ser His Asn Gly Met
 325 330 335
 Gln Phe Ser Thr Trp Asp Asn Asp Asn Asp Lys Phe Glu Gly Asn Cys
 340 345 350
 Ala Glu Gln Asp Gly Ser Gly Trp Trp Met Asn Lys Cys His Ala Gly
 355 360 365
 His Leu Asn Gly Val Tyr Tyr Gln Gly Gly Thr Tyr Ser Lys Ala Ser
 370 375 380
 Thr Pro Asn Gly Tyr Asp Asn Gly Ile Ile Trp Ala Thr Trp Lys Thr
 385 390 395 400
 Arg Trp Tyr Ser Met Lys Lys Thr Thr Met Lys Ile Ile Pro Phe Asn
 405 410 415
 Arg Leu Thr Ile Gly Glu Gly Gln Gln His His Leu Gly Gly Ala Lys
 420 425 430
 Gln Val Arg Pro Glu His Pro Ala Glu Thr Glu Tyr Asp Ser Leu Tyr
 435 440 445
 Pro Glu Asp Asp Leu
 450

<210> 8
 <211> 1152
 <212> PRT
 <213> Homo sapiens

<400> 8
 Met Ala Leu Arg Val Leu Leu Leu Thr Ala Leu Thr Leu Cys His Gly
 1 5 10 15
 Phe Asn Leu Asp Thr Glu Asn Ala Met Thr Phe Gln Glu Asn Ala Arg
 20 25 30
 Gly Phe Gly Gln Ser Val Val Gln Leu Gln Gly Ser Arg Val Val Val
 35 40 45
 Gly Ala Pro Gln Glu Ile Val Ala Ala Asn Gln Arg Gly Ser Leu Tyr
 50 55 60
 Gln Cys Asp Tyr Ser Thr Gly Ser Cys Glu Pro Ile Arg Leu Gln Val
 65 70 75 80

Pro Val Glu Ala Val Asn Met Ser Leu Gly Leu Ser Leu Ala Ala Thr
 85 90 95
 Thr Ser Pro Pro Gln Leu Leu Ala Cys Gly Pro Thr Val His Gln Thr
 100 105 110
 Cys Ser Glu Asn Thr Tyr Val Lys Gly Leu Cys Phe Leu Phe Gly Ser
 115 120 125
 Asn Leu Arg Gln Gln Pro Gln Lys Phe Pro Glu Ala Leu Arg Gly Cys
 130 135 140
 Pro Gln Glu Asp Ser Asp Ile Ala Phe Leu Ile Asp Gly Ser Gly Ser
 145 150 155 160
 Ile Ile Pro His Asp Phe Arg Arg Met Lys Glu Phe Val Ser Thr Val
 165 170 175
 Met Glu Gln Leu Lys Lys Ser Lys Thr Leu Phe Ser Leu Met Gln Tyr
 180 185 190
 Ser Glu Glu Phe Arg Ile His Phe Thr Phe Lys Glu Phe Gln Asn Asn
 195 200 205
 Pro Asn Pro Arg Ser Leu Val Lys Pro Ile Thr Gln Leu Leu Gly Arg
 210 215 220
 Thr His Thr Ala Thr Gly Ile Arg Lys Val Val Arg Glu Leu Phe Asn
 225 230 235 240
 Ile Thr Asn Gly Ala Arg Lys Asn Ala Phe Lys Ile Leu Val Val Ile
 245 250 255
 Thr Asp Gly Glu Lys Phe Gly Asp Pro Leu Gly Tyr Glu Asp Val Ile
 260 265 270
 Pro Glu Ala Asp Arg Glu Gly Val Ile Arg Tyr Val Ile Gly Val Gly
 275 280 285
 Asp Ala Phe Arg Ser Glu Lys Ser Arg Gln Glu Leu Asn Thr Ile Ala
 290 295 300
 Ser Lys Pro Pro Arg Asp His Val Phe Gln Val Asn Asn Phe Glu Ala
 305 310 315 320
 Leu Lys Thr Ile Gln Asn Gln Leu Arg Glu Lys Ile Phe Ala Ile Glu
 325 330 335
 Gly Thr Gln Thr Gly Ser Ser Ser Phe Glu His Glu Met Ser Gln
 340 345 350
 Glu Gly Phe Ser Ala Ala Ile Thr Ser Asn Gly Pro Leu Leu Ser Thr
 355 360 365
 Val Gly Ser Tyr Asp Trp Ala Gly Gly Val Phe Leu Tyr Thr Ser Lys
 370 375 380

Glu Lys Ser Thr Phe Ile Asn Met Thr Arg Val Asp Ser Asp Met Asn
 385 390 395 400
 Asp Ala Tyr Leu Gly Tyr Ala Ala Ala Ile Ile Leu Arg Asn Arg Val
 405 410 415
 Gln Ser Leu Val Leu Gly Ala Pro Arg Tyr Gln His Ile Gly Leu Val
 420 425 430
 Ala Met Phe Arg Gln Asn Thr Gly Met Trp Glu Ser Asn Ala Asn Val
 435 440 445
 Lys Gly Thr Gln Ile Gly Ala Tyr Phe Gly Ala Ser Leu Cys Ser Val
 450 455 460
 Asp Val Asp Ser Asn Gly Ser Thr Asp Leu Val Leu Ile Gly Ala Pro
 465 470 475 480
 His Tyr Tyr Glu Gln Thr Arg Gly Gln Val Ser Val Cys Pro Leu
 485 490 495
 Pro Arg Gly Arg Ala Arg Trp Gln Cys Asp Ala Val Leu Tyr Gly Glu
 500 505 510
 Gln Gly Gln Pro Trp Gly Arg Phe Gly Ala Ala Leu Thr Val Leu Gly
 515 520 525
 Asp Val Asn Gly Asp Lys Leu Thr Asp Val Ala Ile Gly Ala Pro Gly
 530 535 540
 Glu Glu Asp Asn Arg Gly Ala Val Tyr Leu Phe His Gly Thr Ser Gly
 545 550 555 560
 Ser Gly Ile Ser Pro Ser His Ser Gln Arg Ile Ala Gly Ser Lys Leu
 565 570 575
 Ser Pro Arg Leu Gln Tyr Phe Gly Gln Ser Leu Ser Gly Gly Gln Asp
 580 585 590
 Leu Thr Met Asp Gly Leu Val Asp Leu Thr Val Gly Ala Gln Gly His
 595 600 605
 Val Leu Leu Leu Arg Ser Gln Pro Val Leu Arg Val Lys Ala Ile Met
 610 615 620
 Glu Phe Asn Pro Arg Glu Val Ala Arg Asn Val Phe Glu Cys Asn Asp
 625 630 635 640
 Gln Val Val Lys Gly Lys Glu Ala Gly Glu Val Arg Val Cys Leu His
 645 650 655
 Val Gln Lys Ser Thr Arg Asp Arg Leu Arg Glu Gly Gln Ile Gln Ser
 660 665 670
 Val Val Thr Tyr Asp Leu Ala Leu Asp Ser Gly Arg Pro His Ser Arg
 675 680 685

Ala Val Phe Asn Glu Thr Lys Asn Ser Thr Arg Arg Gln Thr Gln Val
 690 695 700

Leu Gly Leu Thr Gln Thr Cys Glu Thr Leu Lys Leu Gln Leu Pro Asn
 705 710 715 720

Cys Ile Glu Asp Pro Val Ser Pro Ile Val Leu Arg Leu Asn Phe Ser
 725 730 735

Leu Val Gly Thr Pro Leu Ser Ala Phe Gly Asn Leu Arg Pro Val Leu
 740 745 750

Ala Glu Asp Ala Gln Arg Leu Phe Thr Ala Leu Phe Pro Phe Glu Lys
 755 760 765

Asn Cys Gly Asn Asp Asn Ile Cys Gln Asp Asp Leu Ser Ile Thr Phe
 770 775 780

Ser Phe Met Ser Leu Asp Cys Leu Val Val Gly Gly Pro Arg Glu Phe
 785 790 795 800

Asn Val Thr Val Thr Val Arg Asn Asp Gly Glu Asp Ser Tyr Arg Thr
 805 810 815

Gln Val Thr Phe Phe Pro Leu Asp Leu Ser Tyr Arg Lys Val Ser
 820 825 830

Thr Leu Gln Asn Gln Arg Ser Gln Arg Ser Trp Arg Leu Ala Cys Glu
 835 840 845

Ser Ala Ser Ser Thr Glu Val Ser Gly Ala Leu Lys Ser Thr Ser Cys
 850 855 860

Ser Ile Asn His Pro Ile Phe Pro Glu Asn Ser Glu Val Thr Phe Asn
 865 870 875 880

Ile Thr Phe Asp Val Asp Ser Lys Ala Ser Leu Gly Asn Lys Leu Leu
 885 890 895

Leu Lys Ala Asn Val Thr Ser Glu Asn Asn Met Pro Arg Thr Asn Lys
 900 905 910

Thr Glu Phe Gln Leu Glu Leu Pro Val Lys Tyr Ala Val Tyr Met Val
 915 920 925

Val Thr Ser His Gly Val Ser Thr Lys Tyr Leu Asn Phe Thr Ala Ser
 930 935 940

Glu Asn Thr Ser Arg Val Met Gln His Gln Tyr Gln Val Ser Asn Leu
 945 950 955 960

Gly Gln Arg Ser Pro Pro Ile Ser Leu Val Phe Leu Val Pro Val Arg
 965 970 975

Leu Asn Gln Thr Val Ile Trp Asp Arg Pro Gln Val Thr Phe Ser Glu
 980 985 990

Asn Leu Ser Ser Thr Cys His Thr Lys Glu Arg Leu Pro Ser His Ser
 995 1000 1005
 Asp Phe Leu Ala Glu Leu Arg Lys Ala Pro Val Val Asn Cys Ser Ile
 1010 1015 1020
 Ala Val Cys Gln Arg Ile Gln Cys Asp Ile Pro Phe Phe Gly Ile Gln
 1025 1030 1035 1040
 Glu Glu Phe Asn Ala Thr Leu Lys Gly Asn Leu Ser Phe Asp Trp Tyr
 1045 1050 1055
 Ile Lys Thr Ser His Asn His Leu Leu Ile Val Ser Thr Ala Glu Ile
 1060 1065 1070
 Leu Phe Asn Asp Ser Val Phe Thr Leu Leu Pro Gly Gln Gly Ala Phe
 1075 1080 1085
 Val Arg Ser Gln Thr Glu Thr Lys Val Glu Pro Phe Glu Val Pro Asn
 1090 1095 1100
 Pro Leu Pro Leu Ile Val Gly Ser Ser Val Gly Gly Leu Leu Leu
 1105 1110 1115 1120
 Ala Leu Ile Thr Ala Ala Leu Tyr Lys Leu Gly Phe Phe Lys Arg Gln
 1125 1130 1135
 Tyr Lys Asp Met Met Ser Glu Gly Gly Pro Pro Gly Ala Glu Pro Gln
 1140 1145 1150

<210> 9
 <211> 1163
 <212> PRT
 <213> Homo sapiens

<400> 9
 Met Thr Arg Thr Arg Ala Ala Leu Leu Leu Phe Thr Ala Leu Ala Thr
 1 5 10 15
 Ser Leu Gly Phe Asn Leu Asp Thr Glu Glu Leu Thr Ala Phe Arg Val
 20 25 30
 Asp Ser Ala Gly Phe Gly Asp Ser Val Val Gln Tyr Ala Asn Ser Trp
 35 40 45
 Val Val Val Gly Ala Pro Gln Lys Ile Thr Ala Ala Asn Gln Thr Gly
 50 55 60
 Gly Leu Tyr Gln Cys Gly Tyr Ser Thr Gly Ala Cys Glu Pro Ile Gly
 65 70 75 80
 Leu Gln Val Pro Pro Glu Ala Val Asn Met Ser Leu Gly Leu Ser Leu
 85 90 95

Ala Ser Thr Thr Ser Pro Ser Gln Leu Leu Ala Cys Gly Pro Thr Val
 100 105 110
 His His Glu Cys Gly Arg Asn Met Tyr Leu Thr Gly Leu Cys Phe Leu
 115 120 125
 Leu Gly Pro Thr Gln Leu Thr Gln Arg Leu Pro Val Ser Arg Gln Glu
 130 135 140
 Cys Pro Arg Gln Glu Gln Asp Ile Val Phe Leu Ile Asp Gly Ser Gly
 145 150 155 160
 Ser Ile Ser Ser Arg Asn Phe Ala Thr Met Met Asn Phe Val Arg Ala
 165 170 175
 Val Ile Ser Gln Phe Gln Arg Pro Ser Thr Gln Phe Ser Leu Met Gln
 180 185 190
 Phe Ser Asn Lys Phe Gln Thr His Leu Thr Phe Glu Glu Phe Arg Arg
 195 200 205
 Thr Ser Asn Pro Leu Ser Leu Leu Ala Ser Val His Gln Leu Gln Gly
 210 215 220
 Phe Thr Tyr Thr Ala Thr Ala Ile Gln Asn Val Val His Arg Leu Phe
 225 230 235 240
 His Ala Ser Tyr Gly Ala Arg Arg Asp Ala Thr Lys Ile Leu Ile Val
 245 250 255
 Ile Thr Asp Gly Lys Glu Gly Asp Thr Leu Asp Tyr Lys Asp Val
 260 265 270
 Ile Pro Met Ala Asp Ala Ala Gly Ile Ile Arg Tyr Ala Ile Gly Val
 275 280 285
 Gly Leu Ala Phe Gln Asn Arg Asn Ser Trp Lys Glu Leu Asn Asp Ile
 290 295 300
 Ala Ser Lys Pro Ser Gln Glu His Ile Phe Lys Val Glu Asp Phe Asp
 305 310 315 320
 Ala Leu Lys Asp Ile Gln Thr Gln Leu Arg Glu Lys Ile Phe Pro Ile
 325 330 335
 Glu Gly Thr Glu Thr Thr Ser Ser Ser Phe Glu Leu Glu Met Ala
 340 345 350
 Gln Glu Gly Phe Ser Ala Val Phe Thr Pro Asp Gly Pro Val Leu Gly
 355 360 365
 Ala Val Gly Ser Phe Thr Trp Ser Gly Gly Ala Phe Leu Tyr Pro Pro
 370 375 380
 Asn Met Ser Pro Thr Phe Ile Asn Met Ser Gln Glu Asn Val Asp Met
 385 390 395 400

Arg Asp Ser Tyr Leu Gly Tyr Ser Thr Glu Leu Ala Leu Trp Lys Gly
 405 410 415
 Val Gln Ser Leu Val Leu Gly Ala Pro Arg Tyr Gln His Thr Gly Lys
 420 425 430
 Ala Val Ile Phe Thr Gln Val Ser Arg Gln Trp Arg Met Lys Ala Glu
 435 440 445
 Val Thr Gly Thr Gln Ile Gly Ser Tyr Phe Gly Pro Ser Leu Cys Ser
 450 455 460
 Val Asp Val Asp Ser Asp Gly Ser Thr Asp Leu Val Leu Ile Gly Pro
 465 470 475 480
 Pro His Tyr Tyr Glu Gln Thr Arg Gly Ala Gln Val Ser Val Cys Pro
 485 490 495
 Leu Pro Arg Gly Trp Arg Arg Trp Trp Cys Asp Ala Val Leu Tyr Gly
 500 505 510
 Glu Gln Gly His Pro Trp Gly Arg Phe Gly Ala Ala Leu Thr Val Leu
 515 520 525
 Gly Asp Val Asn Gly Asp Lys Leu Thr Asp Val Val Ile Gly Ala Pro
 530 535 540
 Gly Glu Glu Glu Asn Arg Gly Ala Val Tyr Leu Phe His Gly Val Leu
 545 550 555 560
 Gly Pro Ser Ile Ser Pro Ser His Ser Gln Arg Ile Ala Gly Ser Gln
 565 570 575
 Leu Ser Ser Arg Leu Gln Tyr Phe Gly Gln Ala Leu Ser Gly Gly Gln
 580 585 590
 Asp Leu Thr Gln Asp Gly Leu Val Asp Leu Ala Val Gly Ala Arg Gly
 595 600 605
 Gln Val Leu Leu Leu Arg Thr Arg Pro Val Leu Trp Val Gly Val Ser
 610 615 620
 Met Gln Phe Ile Pro Ala Glu Ile Pro Arg Ser Ala Phe Glu Cys Arg
 625 630 635 640
 Glu Gln Val Val Ser Glu Gln Thr Leu Val Gln Ser Asn Ile Cys Leu
 645 650 655
 Tyr Ile Asp Lys Arg Ser Lys Asn Leu Leu Gly Ser Arg Asp Leu Gln
 660 665 670
 Ser Ser Val Thr Leu Asp Leu Ala Leu Asp Pro Gly Arg Leu Ser Pro
 675 680 685
 Arg Ala Thr Phe Gln Glu Thr Lys Asn Arg Ser Leu Ser Arg Val Arg
 690 695 700

Val Leu Gly Leu Lys Ala His Cys Glu Asn Phe Asn Leu Leu Leu Pro
 705 710 715 720
 Ser Cys Val Glu Asp Ser Val Thr Pro Ile Thr Leu Arg Leu Asn Phe
 725 730 735
 Thr Leu Val Gly Lys Pro Leu Leu Ala Phe Arg Asn Leu Arg Pro Met
 740 745 750
 Leu Ala Ala Asp Ala Gln Arg Tyr Phe Thr Ala Ser Leu Pro Phe Glu
 755 760 765
 Lys Asn Cys Gly Ala Asp His Ile Cys Gln Asp Asn Leu Gly Ile Ser
 770 775 780
 Phe Ser Phe Pro Gly Leu Lys Ser Leu Leu Val Gly Ser Asn Leu Glu
 785 790 795 800
 Leu Asn Ala Glu Val Met Val Trp Asn Asp Gly Glu Asp Ser Tyr Gly
 805 810 815
 Thr Thr Ile Thr Phe Ser His Pro Ala Gly Leu Ser Tyr Arg Tyr Val
 820 825 830
 Ala Glu Gly Gln Lys Gln Gly Gln Leu Arg Ser Leu His Leu Thr Cys
 835 840 845
 Asp Ser Ala Pro Val Gly Ser Gln Gly Thr Trp Ser Thr Ser Cys Arg
 850 855 860
 Ile Asn His Leu Ile Phe Arg Gly Ala Gln Ile Thr Phe Leu Ala
 865 870 875 880
 Thr Phe Asp Val Ser Pro Lys Ala Val Leu Gly Asp Arg Leu Leu Leu
 885 890 895
 Thr Ala Asn Val Ser Ser Glu Asn Asn Thr Pro Arg Thr Ser Lys Thr
 900 905 910
 Thr Phe Gln Leu Glu Leu Pro Val Lys Tyr Ala Val Tyr Thr Val Val
 915 920 925
 Ser Ser His Glu Gln Phe Thr Lys Tyr Leu Asn Phe Ser Glu Ser Glu
 930 935 940
 Glu Lys Glu Ser His Val Ala Met His Arg Tyr Gln Val Asn Asn Leu
 945 950 955 960
 Gly Gln Arg Asp Leu Pro Val Ser Ile Asn Phe Trp Val Pro Val Glu
 965 970 975
 Leu Asn Gln Glu Ala Val Trp Met Asp Val Glu Val Ser Leu Pro Gln
 980 985 990
 Asn Pro Ser Leu Arg Cys Ser Ser Glu Lys Ile Ala Gly Pro Ala Ser
 995 1000 1005

Asp Phe Leu Ala His Ile Gln Lys Asn Pro Val Leu Asp Cys Ser Ile
 1010 1015 1020

Ala Gly Cys Leu Arg Phe Arg Cys Asp Val Pro Ser Phe Ser Val Gln
 1025 1030 1035 1040

Glu Glu Leu Asp Phe Thr Leu Lys Gly Asn Leu Ser Phe Gly Trp Val
 1045 1050 1055

Arg Gln Ile Leu Gln Lys Lys Val Ser Val Val Ser Val Ala Glu Ile
 1060 1065 1070

Thr Phe Asp Thr Ser Val Tyr Ser Gln Leu Pro Gly Gln Glu Ala Phe
 1075 1080 1085

Met Arg Ala Gln Thr Thr Val Leu Glu Lys Tyr Lys Val His Asn
 1090 1095 1100

Pro Thr Pro Leu Ile Val Gly Ser Ser Ile Gly Gly Leu Leu Leu
 1105 1110 1115 1120

Ala Leu Ile Thr Ala Val Leu Tyr Lys Val Gly Phe Phe Lys Arg Gln
 1125 1130 1135

Tyr Lys Glu Met Met Glu Glu Ala Asn Gly Gln Ile Ala Pro Glu Asn
 1140 1145 1150

Gly Thr Gln Thr Pro Ser Pro Pro Ser Glu Lys
 1155 1160

<210> 10
 <211> 769
 <212> PRT
 <213> Homo sapiens

<400> 10
 Met Leu Gly Leu Arg Pro Pro Leu Leu Ala Leu Val Gly Leu Leu Ser
 1 5 10 15

Leu Gly Cys Val Leu Ser Gln Glu Cys Thr Lys Phe Lys Val Ser Ser
 20 25 30

Cys Arg Glu Cys Ile Glu Ser Gly Pro Gly Cys Thr Trp Cys Gln Lys
 35 40 45

Leu Asn Phe Thr Gly Pro Gly Asp Pro Asp Ser Ile Arg Cys Asp Thr
 50 55 60

Arg Pro Gln Leu Leu Met Arg Gly Cys Ala Ala Asp Asp Ile Met Asp
 65 70 75 80

Pro Thr Ser Leu Ala Glu Thr Gln Glu Asp His Asn Gly Gly Gln Lys
 85 90 95

Gln Leu Ser Pro Gln Lys Val Thr Leu Tyr Leu Arg Pro Gly Gln Ala
 100 105 110

Ala Ala Phe Asn Val Thr Phe Arg Arg Ala Lys Gly Tyr Pro Ile Asp
 115 120 125

Leu Tyr Tyr Leu Met Asp Leu Ser Tyr Ser Met Leu Asp Asp Leu Arg
 130 135 140

Asn Val Lys Lys Leu Gly Gly Asp Leu Leu Arg Ala Leu Asn Glu Ile
 145 150 155 160

Thr Glu Ser Gly Arg Ile Gly Phe Gly Ser Phe Val Asp Lys Thr Val
 165 170 175

Leu Pro Phe Val Asn Thr His Pro Asp Lys Leu Arg Asn Pro Cys Pro
 180 185 190

Asn Lys Glu Lys Glu Cys Gln Pro Pro Phe Ala Phe Arg His Val Leu
 195 200 205

Lys Leu Thr Asn Asn Ser Asn Gln Phe Gln Thr Glu Val Gly Lys Gln
 210 215 220

Leu Ile Ser Gly Asn Leu Asp Ala Pro Glu Gly Gly Leu Asp Ala Met
 225 230 235 240

Met Gln Val Ala Ala Cys Pro Glu Glu Ile Gly Trp Arg Asn Val Thr
 245 250 255

Arg Leu Leu Val Phe Ala Thr Asp Asp Gly Phe His Phe Ala Gly Asp
 260 265 270

Gly Lys Leu Gly Ala Ile Leu Thr Pro Asn Asp Gly Arg Cys His Leu
 275 280 285

Glu Asp Asn Leu Tyr Lys Arg Ser Asn Glu Phe Asp Tyr Pro Ser Val
 290 295 300

Gly Gln Leu Ala His Lys Leu Ala Glu Asn Asn Ile Gln Pro Ile Phe
 305 310 315 320

Ala Val Thr Ser Arg Met Val Lys Thr Tyr Glu Lys Leu Thr Glu Ile
 325 330 335

Ile Pro Lys Ser Ala Val Gly Glu Leu Ser Glu Asp Ser Ser Asn Val
 340 345 350

Val His Leu Ile Lys Asn Ala Tyr Asn Lys Leu Ser Ser Arg Val Phe
 355 360 365

Leu Asp His Asn Ala Leu Pro Asp Thr Leu Lys Val Thr Tyr Asp Ser
 370 375 380

Phe Cys Ser Asn Gly Val Thr His Arg Asn Gln Pro Arg Gly Asp Cys
 385 390 395 400

Asp Gly Val Gln Ile Asn Val Pro Ile Thr Phe Gln Val Lys Val Thr
 405 410 415

Ala Thr Glu Cys Ile Gln Glu Gln Ser Phe Val Ile Arg Ala Leu Gly
 420 425 430

Phe Thr Asp Ile Val Thr Val Gln Val Leu Pro Gln Cys Glu Cys Arg
 435 440 445

Cys Arg Asp Gln Ser Arg Asp Arg Ser Leu Cys His Gly Lys Gly Phe
 450 455 460

Leu Glu Cys Gly Ile Cys Arg Cys Asp Thr Gly Tyr Ile Gly Lys Asn
 465 470 475 480

Cys Glu Cys Gln Thr Gln Gly Arg Ser Ser Gln Glu Leu Glu Gly Ser
 485 490 495

Cys Arg Lys Asp Asn Asn Ser Ile Ile Cys Ser Gly Leu Gly Asp Cys
 500 505 510

Val Cys Gly Gln Cys Leu Cys His Thr Ser Asp Val Pro Gly Lys Leu
 515 520 525

Ile Tyr Gly Gln Tyr Cys Glu Cys Asp Thr Ile Asn Cys Glu Arg Tyr
 530 535 540

Asn Gly Gln Val Cys Gly Gly Pro Gly Arg Gly Leu Cys Phe Cys Gly
 545 550 555 560

Lys Cys Arg Cys His Pro Gly Phe Glu Gly Ser Ala Cys Gln Cys Glu
 565 570 575

Arg Thr Thr Glu Gly Cys Leu Asn Pro Arg Arg Val Glu Cys Ser Gly
 580 585 590

Arg Gly Arg Cys Arg Cys Asn Val Cys Glu Cys His Ser Gly Tyr Gln
 595 600 605

Leu Pro Leu Cys Gln Glu Cys Pro Gly Cys Pro Ser Pro Cys Gly Lys
 610 615 620

Tyr Ile Ser Cys Ala Glu Cys Leu Lys Phe Glu Lys Gly Pro Phe Gly
 625 630 635 640

Lys Asn Cys Ser Ala Ala Cys Pro Gly Leu Gln Leu Ser Asn Asn Pro
 645 650 655

Val Lys Gly Arg Thr Cys Lys Glu Arg Asp Ser Glu Gly Cys Trp Val
 660 665 670

Ala Tyr Thr Leu Glu Gln Gln Asp Gly Met Asp Arg Tyr Leu Ile Tyr
 675 680 685

Val Asp Glu Ser Arg Glu Cys Val Ala Gly Pro Asn Ile Ala Ala Ile
 690 695 700

Val Gly Gly Thr Val Ala Gly Ile Val Leu Ile Gly Ile Leu Leu Leu
 705 710 715 720

Val Ile Trp Lys Ala Leu Ile His Leu Ser Asp Leu Arg Glu Tyr Arg
725 730 735

Arg Phe Glu Lys Glu Lys Leu Lys Ser Gln Trp Asn Asn Asp Asn Pro
740 745 750

Leu Phe Lys Ser Ala Thr Thr Val Met Asn Pro Lys Phe Ala Glu
755 760 765

Ser

<210> 11
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 11
Lys Gln Ala Gly Asp Val
1 5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Lars BJÖRCK et al.

Title: METHOD FOR IDENTIFYING AN ANTI-STREPTOCOCCAL AGENT AND ITS USE FOR TREATING STREPTOCOCCAL INFECTIONS

Appl. No.: 10/553,904

International Filing Date: 04/23/2004

371(c) Date: 03/29/2006

Examiner: Unassigned

Art Unit: Unassigned

Confirmation Number: 7961

PRELIMINARY AMENDMENT UNDER 37 CFR 1.115

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Notification of Defective Response mailed November 20, 2006, please amend the application as follows:

Amendments to the Specification begin on page 2 of this document.

Remarks/Arguments begin on page 9 of this document.

Please amend the application as follows:

Amendments to the Specification:

Please delete the paragraph on page 6, lines 12-21 and replace it with the following paragraph:

Figure 5 shows inhibition of the M1-protein-induced HBP release by fibrinogen derived peptides and antibodies to CD18. *Panel A*: Human plasma was incubated with peptides Gly-Pro-Arg-Pro (**SEQ ID NO: 2**), Gly-His-Arg-Pro (**SEQ ID NO: 3**) (100 µg/ml), or buffer alone for 15 min at 37°C. Clotting was initiated by the addition of thrombin and the clotting time was determined. *Panel B*: M1 protein was added to whole human blood (1 µg/ml) followed by the addition of different amounts of Gly-Pro-Arg-Pro (**SEQ ID NO: 2**), Gly-His-Arg-Pro (**SEQ ID NO: 3**), antibody mAB IB4 to CD18, or antibody AS88 (directed against human H-kininogen). After 30 min of incubation at 37°C, cells were centrifuged and the amount of HBP in the supernatants was determined. Data are expressed as percent of HBP release induced by M1 protein alone, and the bars represent means ± SD of 3 experiments, each done in duplicate.

Please delete the paragraph on page 12, lines 18-29 and replace it with the following paragraph:

The second component comprises isolated fibrinogen or a functional variant thereof. Fibrinogen is a soluble plasma protein which is converted to insoluble fibrin in the blood by the action of the enzyme thrombin. This contributes to the formation of a blood clot. Fibrinogen is composed of six peptide chains. These are arranged in two identical subunits, each composed of an A α , a B β and a γ chain, joined by disulphide bonds. Streptococcal M protein binds to fibrinogen (Kantor, 1965, J. Exp. Med., 121, 849-859) with high affinity (Åkesson et al., 1994, Biochem. J., 300, 877-886; Berge et al., 1997, J. Biol. Chem., 272, 20774-20781). Fibrinogen also binds to PMNs via β_2 integrins (Altieri, 1999, Thromb. Haemost., 82, 781-786). The binding site for the β_2 integrin Mac1 has been mapped to the N-terminal region of the A γ chain of fibrinogen. In addition, the unique sequence KQAGDV (**SEQ ID NO: 11**), which is found at the C-terminal end of the γ chain, is essential for integrin binding.

Please delete the paragraph on page 24, line 28 to page 25, line 21 and replace it with the following paragraph:

Reagents. Neutrophil Isolation Medium (NIM) was purchased from Cardinal Associates Inc. (Santa Fe, NM). RPMI 1640 medium with Glutamax I (trade mark), Minimum Essential Medium (MEM) with Earle's salts and L-glutamine, fetal bovine serum, and penicillin (5000 units/ml) / streptomycin (5000 µg/ml) solution were purchased from Life Technologies (Täby, Sweden). Ionomycin and formyl-methionyl-leucyl-phenylalanine (fMLP) were obtained from Calbiochem (La Jolla, CA). The acetoxymethyl ester of N,N'-(1,2-ethanediylbis(oxy-2,1-phenylene))bis(N-(carboxymethyl)) (BAPTA), and ProLong® Antifade Kit were from Molecular Probes (Eugene, OR). 4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid (HEPES) was from Merck (Whitehouse Station, NJ). Streptococcal cysteine proteinase (SpeB) zymogen was purified from the medium of AP1 bacteria by ammonium sulfate precipitation (80 % w/v) followed by fractionation on S-Sepharose (Berge et al., 1997, J. Biol. Chem., 272, 20774-20781). Recombinant M1 protein, fragments A-S and S-C3, and protein H were obtained by expression in E. coli and purified as described earlier (Åkesson et al., 1994, Biochem. J., 300, 877-886; Berge et al., 1997, J. Biol. Chem., 272, 20774-20781). Recombinant human HBP was produced using the baculovirus expression system in Sf9 insect cells (Invitrogen Corp., Carlsbad, California) and was purified as described (Laemmli, 1970, Nature, 227, 680-685). Lipoteichoic acid (LTA), hyaluronic acid (HA), and bovine serum albumin (BSA) were from Sigma Chemical Co. (St. Louis, MO). Mouse mAB 2F23C3 and rabbit antiserum (409A) to recombinant HBP were prepared and purified as described earlier (Lindmark et al., J. Leukoc. Biol., 66, 634-643) and peroxidase-conjugated goat anti-rabbit IgG was from Bio-Rad Laboratories (Richmond, CA). Peptides H-2935 (Gly-Pro-Arg-Pro (**SEQ ID NO: 2**)) and H-2940 (Gly-His-Arg-Pro (**SEQ ID NO: 3**)) were purchased from Bachem Feinchemikalien AG (Bubendorf, Switzerland). Fluanison/fentanyl and midazolam were from Janssen Pharmaceutica, Beers, Belgium and Hoffman-La Roche, Basel, Switzerland.

Please delete the paragraph on page 28, line 27 to page 29, line 4 and replace it with the following paragraph:

RT-PCR - RT-PCR was conducted with GeneAmp/PerkinElmer RNA PCR kit according to the manufacturer's protocol. Briefly, total RNA (500 ng) in water was heated (65°C, 10 min), chilled on ice, and reverse transcribed (20 min, 42°GG GTT GTT GAG AA 3' (SEQ ID NO: 4) derived from the genomic sequence (NM 001700) of human HBP), 1 U/μl RNase inhibitor, and 2.5 % de-ionized formamide. After denaturation (5 min, 99°C), samples were amplified in PCR buffer (1.5 mM MgCl₂, 0.2 mM dNTPs, 1 μM primer, 2.5% de-ionized formamide, and 0.05 1 U/μl *Taq* polymerase) for 20-35 cycles with annealing between 50 and 60°C and extension at 72°C, using a PerkinElmer/GeneAmp PCR system 2400. Products were analyzed by agarose gel electrophoresis (1% gels).

Please delete the paragraph on page 29, lines 5-19 and replace it with the following paragraph:

Animals - Adult male mice (approximately 30 g) of the C57BL/6 strain were used. Animals were anaesthetized with equal parts of fluanison/fentanyl (Hypnorm 10, 0.2 mg/ml) and midazolam (Dormicum, 5 mg/ml) diluted 1:1 with sterile water (dose: 0.2 ml / mouse i.m.). The anaesthesia was supplemented with inhalation of 2% isoflurane. All animal experiments were approved by the regional ethical committee. Mice were given an intravenous injection of 100 μl of a solution containing 150 μg/ml M1 protein. Alternatively, 100 μl of a solution containing 150 μg/ml M1 protein and 4 mg/ml Gly-Pro-Arg-Pro (SEQ ID NO: 2) or Gly-His-Arg-Pro (SEQ ID NO: 3) were intravenously injected. As control vehicle alone was applied via the same route. 30 min after injection, mice were sacrificed and the lungs were removed. Alternatively, 100 μl of a bacteria solution (2 × 10⁹ AP1 bacteria/ml in the presence or absence of 400 μg Gly-Pro-Arg-Pro (SEQ ID NO: 2) or Gly-His-Arg-Pro (SEQ ID NO: 3)) were injected together with 0,9 ml of air into the dorsal region of the mouse. After 30 min, mice were given an intravenous injection of 100 μl of a solution containing PBS or 2 mg/ml Gly-Pro-Arg-Pro (SEQ ID NO: 2) or Gly-His-Arg-Pro (SEQ ID NO: 3), respectively. Six hours after infection, mice were sacrificed and the lungs were removed.

Please delete the paragraphs on page 35, line 30 to page 37, line 8 and replace them with the following paragraphs:

Human fibrinogen binds to PMNs via β_2 integrins (Altieri, 1999, Thromb. Haemost., **82**, 781-786) and for CD11c/CD18 the binding site was mapped to the NH₂-terminal region of the A α chain of fibrinogen. A peptide derived from this region (Gly-Pro-Arg-Pro; **SEQ ID NO: 2**), has been shown to block adherence of TNF-stimulated PMNs to fibrinogen-coated surfaces, while other peptides from the same region, including Gly-His-Arg-Pro (**SEQ ID NO: 3**), had no effect (Loike et al., 1991, Proc. Natl. Acad. Sci. USA, **88**, 1044-1048). Furthermore, it was demonstrated that antibodies against β_2 integrins inhibit the binding of fibrinogen to activated PMNs, and among these antibodies a monoclonal antibody (IB4) directed against the common β -chain of integrins, was the most potent (Loike et al., 1991, Proc. Natl. Acad. Sci. USA, **88**, 1044-1048). Platelet-induced activation of PMNs was also found to be dependent on the interaction between CD11c/CD18 and the A α chain of platelet-expressed fibrinogen (Ruf and Patschke, 1995, Br. J. Haematol., **90**, 791-796). As shown for the binding of fibrinogen to PMNs, platelet-induced activation was also inhibited by the Gly-Pro-Arg-Pro (**SEQ ID NO: 2**) peptide and by antibodies to CD11c, whereas the Gly-His-Arg-Pro (**SEQ ID NO: 3**) peptide had no effect. These reports indicate that the binding of PMNs to immobilized fibrinogen (for instance on coverslips or platelets) involves the β_2 integrins leading to an activation of PMNs. Interestingly, Gly-Pro-Arg-Pro (**SEQ ID NO: 2**) not only inhibits the binding of fibrinogen to β_2 integrins, but it also prevents clot formation (Laudano and Doolittle, 1980, Biochemistry, **19**, 1013-1019), and Figure 5A shows that Gly-Pro-Arg-Pro (**SEQ ID NO: 2**) completely blocked thrombin-induced coagulation of normal plasma, while Gly-His-Arg-Pro (**SEQ ID NO: 3**) did not influence the clotting time. It should be emphasized that Gly-Pro-Arg-Pro (**SEQ ID NO: 2**) prevents fibrin-fiber formation by binding to the thrombin exposed polymerization sites of the fibrin molecules (Spraggan et al., 1997, Nature, **389**, 455-462). Thus, the effect of Gly-Pro-Arg-Pro (**SEQ ID NO: 2**) on clot-formation is not integrin-dependent. The influence of the two peptides on the interaction between M1 protein and fibrinogen was tested in a competitive ELISA. However, none of the peptides had an effect in these assays (data not shown).

The Gly-Pro-Arg-Pro (**SEQ ID NO: 2**) and Gly-His-Arg-Pro (**SEQ ID NO: 3**) peptides, as well as antibodies to the β_2 integrins (IB4), were also tested for their ability to interfere with the M1 protein-induced secretion of HBP. As shown in Figure 5B, the addition of Gly-Pro-Arg-Pro (**SEQ ID NO: 2**) to human blood blocked the mobilization of HBP by M1 protein in a dose dependent manner, and also antibody IB4 directed against the common β -chain of integrins impaired the release. The control substances, Gly-His-Arg-Pro (**SEQ ID NO: 3**) and an unrelated antibody to H-kininogen, did not influence HBP secretion (Fig. 5B). The effect of Gly-Pro-Arg-Pro (**SEQ ID NO: 2**) on M1 protein-induced PMN aggregation was confirmed by scanning electron microscopy analysis. Gly-Pro-Arg-Pro (**SEQ ID NO: 2**) inhibited the aggregation of purified PMNs in a mixture of plasma and M1 protein. In contrast, Gly-His-Arg-Pro (**SEQ ID NO: 3**) had no effect on the aggregation of PMNs. These results support the notion that M1 protein-fibrinogen complexes activate PMNs through β_2 integrin ligation, which triggers the release of HBP. This mechanism appears to be similar to the previously described antibody-mediated cross-linking of CD11b/CD18 that mimics adhesion-dependent receptor engagement causing a massive release of HBP from PMNs (Gautam et al., 2000, J. Exp. Med., 191, 1829-1839).

Please delete the paragraphs on page 37, line 11 to page 39, line 18 and replace them with the following paragraphs:

So far, HBP has only been identified in humans and pigs (Flodgaard et al, 1991, Eur J. Biochem, 197, 535-547). Before mouse experiments were performed, we investigated whether an HBP homologue is also present in the mouse. To this end, bone marrow cells from mice were isolated and the existence of a murine HBP homologue was demonstrated by RT-PCR analysis and Western blot analysis. RT-PCR amplification of RNA prepared from bone marrow cells was carried out using a primer set derived from the human HBP sequence. Western blot detection was carried out after electrophoresis of human HPB and murine bone marrow lysate immunostained with antibodies against human HBP. A series of animal experiments was then conducted with anaesthetized mice. Three mice received M1 protein i.v. (15 μ g/animal); three were treated with a mixture of M1 protein (15 μ g/animal) and peptide Gly-Pro-Arg-Pro (**SEQ ID NO: 2**) (400 μ g/animal); three with a mixture of M1

protein (15 µg/animal) and peptide Gly-His-Arg-Pro (SEQ ID NO: 3) (400 µg/animal); and three with vehicle alone. Thirty minutes after administration the breathing of mice injected with M1 protein or M1 protein plus peptide Gly-His-Arg-Pro (SEQ ID NO: 3) was clearly affected as compared to the other mice. The animals were sacrificed and the lungs were removed, stained with hematoxylin and eosin and subjected to light microscopy or analyzed by scanning electron microscopy. A representative lung sample from a mouse injected with buffer only showed intact lung tissue. Lung sections from mice injected with M1 protein, however, demonstrated severe hemorrhage and tissue destruction. These lesions were almost completely prevented when M1 protein was injected together with Gly-Pro-Arg-Pro (SEQ ID NO: 2), even though the tissue remained slightly swollen which is a sign of an ongoing inflammatory reaction. By contrast, application of Gly-His-Arg-Pro (SEQ ID NO: 3) could not prevent the M1 protein induced bleeding and tissue destruction. Protein H was injected as a control and analysis of the lung tissue revealed no hemorrhage and the alveoli appeared less swollen. In order to resolve lung lesions at higher magnification, tissue sections were analyzed by scanning electron microscopy. A lung section from a PBS-treated mouse showed no signs of any pulmonary damage. However, injection of the M1 protein resulted in severe leakage of erythrocytes as seen before, but also in the deposition of proteinous aggregates. The morphology of the aggregates resembled the M1 protein-induced amorphous plasma precipitates seen earlier. The lungs of mice injected with M1 protein and Gly-Pro-Arg-Pro (SEQ ID NO: 2) contained no precipitates. However, some alveolar swelling and minor leakage of erythrocytes were observed indicating an inflammatory reaction. In contrast, treatment with Gly-His-Pro-Arg (SEQ ID NO: 3) did not influence M1 protein-caused lung damage. The injection of protein H did neither cause serious bleeding nor did the tissue appear to be severely inflamed.

In order to quantify the degree of lung affection six randomly chosen lung tissue section from each of the twelve animals were analyzed by electron microscopy, and the ratio of lung area containing protein aggregates versus total lung area was determined. Less than 10% of the lung tissue of animal injected with buffer alone or with M1 protein plus the Gly-Pro-Arg-Pro (SEQ ID NO: 2) peptide contained protein aggregates ($3 \pm 1\%$ and $6 \pm 2\%$, respectively). In contrast, 90% of the lungs of animals treated with M1 protein or a mixture of M1 protein and the Gly-His-Arg-Pro (SEQ ID NO: 3) peptide contained protein aggregates ($90 \pm 2\%$ in

both cases). These animal experiments suggest that M1 protein-fibrinogen aggregates activate PMNs via the β_2 integrins, resulting in massive vascular leakage and deposition of protein aggregates in the lung tissue. The results also show that this pathophysiological effect can be blocked when fibrinogen-induced crosslinking of β_2 integrins is prevented by the Gly-Pro-Arg-Pro (SEQ ID NO: 2) peptide.

Gly-Pro-Arg-Pro prevents vascular leakage and lung damage in mice infected with M1 protein expressing *S. pyogenes* bacteria

In a second series of animal experiments, nine mice were subcutaneously infected with M1 protein expressing *S. pyogenes* bacteria. Three mice in each group were treated with peptides Gly-Pro-Arg-Pro (SEQ ID NO: 2) and Gly-His-Arg-Pro (SEQ ID NO: 3) as described in Material and Methods, respectively, while three mice received no treatment. As a control, three mice were given a subcutaneous injection of PBS. Six hours after infection, animals were sacrificed, lungs removed and examined by scanning electron microscopy. Analysis of blood samples from the animals revealed no occurrence of streptococci, indicating that bacteria had not started to disseminate from the site of infection. Electron micrographs of representative lung tissue sections from these animals were obtained. Recovered lungs from mice that received buffer instead of bacteria showed no signs of pulmonary damage. However, mice that were infected with streptococci were suffering from severe lung lesions indicated by massive infiltration of erythrocytes and fibrin deposition. When infected animals were treated with Gly-Pro-Arg-Pro (SEQ ID NO: 2), the lungs appeared to be much less affected, whereas treatment with Gly-His-Arg-Pro (SEQ ID NO: 3) failed to prevent pulmonary damage. Lungs from mice infected with streptococci were further analyzed by immuno-staining electron microscopy by using antibodies against M1 protein. This showed that the M1 protein was found in the infiltrated precipitates. In contrast, no M1 protein staining was observed when lungs from non-infected animals were examined. Taken together, these results suggest that in an infectious model, shedded M1 protein is found in the circulation prior to dissemination of bacteria forming precipitates that deposits in the lungs of infected animals.

REMARKS

The foregoing amendments are made to insert the required SEQ ID NO identifiers associated with various listed sequences. No new matter is entered.

Applicants believe that the present application is now in condition for allowance. Favorable reconsideration of the application as amended is respectfully requested.

The Examiner is invited to contact the undersigned by telephone if it is felt that a telephone interview would advance the prosecution of the present application.

Respectfully submitted,

Date December 20, 2006

By Michael D. Kaminski

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5490
Facsimile: (202) 672-5399

Michael D. Kaminski
Attorney for Applicant
Registration No. 32,904



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/553,904	Lars Bjorck	053694-0131
INTERNATIONAL APPLICATION NO.		
PCT/EP04/04429		
I.A. FILING DATE	PRIORITY DATE	
04/23/2004	04/23/2003	
CONFIRMATION NO. 7961		
371 FORMALITIES LETTER		
 *OC000000021287879*		

Date Mailed: 11/20/2006

NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495)

- Priority Document
- Copy of the International Application filed on 10/21/2005
- Copy of the International Search Report filed on 10/21/2005
- Preliminary Amendments filed on 10/21/2005
- Information Disclosure Statements filed on 03/29/2006
- Oath or Declaration filed on 03/29/2006
- U.S. Basic National Fees filed on 10/21/2005
- Priority Documents filed on 10/21/2005
- Power of Attorney filed on 10/21/2005
- Specification filed on 10/21/2005
- Claims filed on 10/21/2005
- Abstracts filed on 10/21/2005
- Drawings filed on 10/21/2005
- Paper nucleotide sequence listings filed on 10/21/2005

Applicant's response filed 03/29/2006 is hereby acknowledged. The following requirements set forth in the NOTIFICATION of MISSING REQUIREMENTS mailed 04/27/2006 have not been completed.

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825

(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

- This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c). Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.
<https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at <http://www.uspto.gov/ebc>.

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

PAULETTE R KIDWELL

Telephone: (703) 308-9140 EXT 216

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.

10/553,904

INTERNATIONAL APPLICATION NO.

PCT/EP04/04429

ATTY. DOCKET NO.

053694-0131

FORM PCT/DO/EO/916 (371 Formalities Notice)



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/553,904	Lars Bjorck	053694-0131

22428
 FOLEY AND LARDNER LLP
 SUITE 500
 3000 K STREET NW
 WASHINGTON, DC 20007

INTERNATIONAL APPLICATION NO.

PCT/EP04/04429

I.A. FILING DATE	PRIORITY DATE
04/23/2004	04/23/2003

CONFIRMATION NO. 7961

371 FORMALITIES LETTER



OC039000018637442

Date Mailed: 04/27/2006

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

PAULETTE R KIDWELL

Telephone: (703) 308-9140 EXT 216

PART 2 - OFFICE COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/553,904	PCT/EP04/04429	053694-0121

FORM FCT/DO/EO/922 (371 Formalities Notice)

Daily Mail Report for 4/28/2006**PTO Mail Received:**

Delivered	Case Typ	App/Reg No	CInt/Mttr	Action	Atty
Pat		11/311639		Notice of Recordatioin of Assignment Document	
TM		75/413596		Notice of Recordatioin of Assignment Document	
Pat		11/335526		Notice of Recordatioin of Assignment Document	
Pat		11/338718		Notice of Recordatioin of Assignment Document	
Pat		11/335730		Notice of Recordatioin of Assignment Document	
TM		75/756555		Office Action	
Pat		10/302036		Notice of Allowance and Fee(s) Due	
Pat		10/953381		Notice of Allowance and Fee(s) Due	
Pat		10/381333		Notice of Abandonment	
TM		78/574118		Notice of Abandonment	
TM		78/674543		Notice of Publication Under 12(a)	
Pat		10/359289		Office Action Summary	
Pat		11/078661		Office Action Summary	
Pat		10/485546		Office Action Summary	
Pat		11/276080		Office Action Summary	
Pat		10/712259		Office Action Summary	
Pat		09/910778		Office Action Summary	
Pat		10/024050		Office Action Summary	

Other Mail Received:

Daily Mail Report for 5/1/2006**PTO Mail Received:**

Delivered	Case Typ	App/Reg No	CInt/Mttr	Action	Atty
Pat		11/302139		Notice of recordatioin of assignment document	
Pat		10/553404		Notice of recordatioin of assignment document	
Pat		11/269896		Notice of recordatioin of assignment document	
Pat		11/266488		Notice of recordatioin of assignment document	
Pat		10/463582		Notice of recordatioin of assignment document	
Pat		10/551181		Notice of recordatioin of assignment document	
Pat		11/330390		Updated Filing Receiptq	
Pat		09/748143		advisory action before the filing of and appeal brief	
Pat		11/340761		Notice of recordatioin of assignment document	
Pat		09/258405		NOTICE REGARDING CHANGE OF POWER OF ATTORNEY (TRANSFERRED TO TAR)	
Pat		10/148543		advisory action before the filing of and appeal brief	
Pat		10/942083		office communication	
Pat		29/257136		Notice of Missing Parts & Filing Receipt	
Pat		11/373501		Notice of Missing Parts & Filing Receipt	
Pat		60/717197		NOTICE REGARDING CHANGE OF POWER OF ATTORNEY (TRANSFERRED TO TAR)	
Pat		11/373500		Updated Filing Receiptq	
Pat		11/391239		Filing receipt	
Pat		11/390203		Filing receipt	
Pat		11/392679		Filing receipt	
Pat		11/002097		Notice of allowance	
Pat		09/761775		RESPONSE TO RULE 312 COMMUNICATION	
Pat		10/963743		Notice of allowance	
Pat		10/695800		Notice of allowance	
Pat		10/507118		Communication	
Pat		11/329389		Updated Filing Receiptq	
Pat		10/717518		Issue notification	
Pat		10/540111		NOtificaiton of missing requirements	
Pat		09/258405		DECISION ON REQUEST TO WITHDRAW FROM RECORD	
Pat		11/327652		upddated Filing Receipt	
Pat		11/297636		Updated Filing Receiptq	
Pat		11/253758		Updated Filing Receiptq	

Pat	10/080245	priority ack.
Pat	60/750039	Corrected Filing Filing Receipt
Pat	09/770376	Maintenance fee statement
TM	78/433311	Certificate of Registration
TM	78/388584	Certificate of Registration
TM	76/571973	Certificate of Registration

First Previous Next Last

Daily Mail Report for 5/1/2006

Pat	09/873298	Notice of Abandonment
Pat	10/140293	advisory action before the filing of and appeal brief
Pat	11/016982	Notice of Allowance and Fee(s) Due
Pat	10/629740	Notice of Allowance and Fee(s) Due
Pat	10/473576	Office Action Summary
Pat	11/038178	Office Action Summary
Pat	10/006618	Office Action Summary
Pat	10/738115	Office Action Summary
Pat	10/986760	Office Action Summary
Pat	09/942023	Office Action Summary
Pat	10/727037	Office Action Summary
Pat	10/917559	Office Action Summary
Pat	10/553189	Office Action Summary
Pat	10/812307	Office Action Summary
Pat	10/885975	Office Action Summary
Pat	11/050826	Office Action Summary
Pat	10/472091	Office Action Summary
Pat	11/008257	Office Action Summary
Pat	09/558421	Before the Board of Patent Appeals and Interferences
Pat	10/563024	Notice of Acceptance of Application Under 35 U.S.C. 371 AND 37 CFR 1.495
Pat	11369018	Notice of File Missing Parts of Nonprovisional Application
Pat	10/799770	Notice of Allowance and Fee(s) Due
Pat	10/604139	Notice of Allowance and Fee(s) Due
Pat	10/886612	Office Action Summary
Pat	PCT/US2006/008571	NOTIFICATION CONCERNING PAYMENT OF PRESCRIBED FEES
Pat	PCT/US2005/047255	Communication in Cases for WHICH NO OTHER FORM is APPLICABLE
Pat	10/044964	INFORMATION DISCLOSURE STATEMENTS
Pat	11/391240	Filing Receipt
Pat	11/324778	Updated Filing Receipt
Pat	11/166113	ISSUE NOTIFICATION
Pat	09/985299	ISSUE NOTIFICATION
Pat	10/998664	ISSUE NOTIFICATION
Pat	10/930772	ISSUE NOTIFICATION
Pat	10/932072	ISSUE NOTIFICATION
Pat	10/114038	ISSUE NOTIFICATION
Pat	10/513681	ISSUE NOTIFICATION
Pat	10/608041	ISSUE NOTIFICATION
Pat	10/796290	ISSUE NOTIFICATION
Pat	10/805514	ISSUE NOTIFICATION
Pat	10/704556	ISSUE NOTIFICATION
Pat	10/802039	ISSUE NOTIFICATION
Pat	10/394202	ISSUE NOTIFICATION

[First](#) [Previous](#) [Next](#) [Last](#)

Daily Mail Report for 5/1/2006

Pat	10/368493	ISSUE NOTIFICATION
Pat	09/659151	ISSUE NOTIFICATION
Pat	10/667462	ISSUE NOTIFICATION
Pat	10/450139	ISSUE NOTIFICATION
Pat	10/230170	ISSUE NOTIFICATION
Pat	10/806472	ISSUE NOTIFICATION
Pat	10/716498	ISSUE NOTIFICATION
Pat	11/014088	ISSUE NOTIFICATION
Pat	10/511726	ISSUE NOTIFICATION
Pat	10/796141	ISSUE NOTIFICATION
Pat	10/651217	ISSUE NOTIFICATION
Pat	11/136474	Office Action Summary
Pat	11/339444	Notice of Recordatioin of Assignment Document
Pat	10/548590	NOTIFICATION OT COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND /OR AMINO ACID SEQUENCE DISCLOSURES
Pat	10/563796	Notification of Missig Requirements Under 35 U.S.C 371
Pat	10/566099	Notification of Missig Requirements Under 35 U.S.C 371
Pat	11/399604	notice to file missing parts of nonprovisional application
Pat	10/595082	notice of acceptance of application under 35 U.S.C. 371 AND 37 CFR 1.495
Pat	10/548763	notice of acceptance of application under 35 U.S.C. 371 AND 37 CFR 1.495
Pat	10/479225	notice of acceptance of application under 35 U.S.C. 371 AND 37 CFR 1.495
Pat	10/563090	notice of acceptance of application under 35 U.S.C. 371 AND 37 CFR 1.495
Pat	60/789600	Filing Receipt
Pat	60/791895	Filing Receipt
Pat	60/791896	Filing Receipt
Pat	10/196354	Notice of Allowance and Fee(s) Due
Pat	10/848504	Notice of Allowance and Fee(s) Due
Pat	11/000502	Notice of Allowance and Fee(s) Due
Pat	10/724393	ISSUE NOTIFICATION
Pat	10/509631	ISSUE NOTIFICATION
Pat	10/177137	ISSUE NOTIFICATION
Pat	10/980809	ISSUE NOTIFICATION
Pat	10/895347	ISSUE NOTIFICATION
Pat	09/984420	ISSUE NOTIFICATION

Pat 10/800627
Pat 09/984772

ISSUE NOTIFICATION
ISSUE NOTIFICATION

[First](#) [Previous](#) [Next](#) [Last](#)

Daily Mail Report for 5/1/2006

Pat	10/025962	ISSUE NOTIFICATION
Pat	09/733033	ISSUE NOTIFICATION
Pat	10/492190	ISSUE NOTIFICATION
Pat	10/071234	ISSUE NOTIFICATION
TM	78/389475	notice of publication under 12(a)

Other Mail Received:[First](#) [Previous](#) [Next](#) [Last](#)

Daily Mail Report for 5/2/2006

PTO Mail Received:

Delivered	Case Typ	App/Reg No	CInt/Mttr	Action	Atty
Pat		11/350271		Updated Filing Receiptq	
Pat		10/393936		Notice of non-Compliant Amendment (
TM		75/869302		Acknowledgement of Request to	
				Withdraw As Attorney of Record	
TM		75/818089		Acknowledgement of Request to	
				Withdraw As Attorney of Record	
Pat		09/704791		interview summary	
TM		78/733862		examiners amendmnet	
Pat		10/293941		Office Action Summary	
Pat		10/494242		Office Action Summary	
Pat		10/765853		Office Action Summary	
Pat		10/913824		Notice of acceptance of poa	
Pat		10/559610		Notice of recordatioin of assignment document	
Pat		11/344127		Notice of recordatioin of assignment document	
Pat		11/344042		Notice of recordatioin of assignment document	
Pat		11/257395		Notice of recordatioin of assignment document	
Pat		10/474357		Notice of abandonment	
Pat		10/633532		Notice of abandonment	
Pat		11/399063		Notice of Missing Parts & Filing Receipt	
Pat		29/257142		Notice of Missing Parts & Filing Receipt	
Pat		11/339564		Noice of Non-Compliant Amendment (37CFR 1.121)	
Pat	PCT/US2004/0		26810	COMMUNICATION IN CASES FOR WHICH NO OTHER FORM IS APPLICABLE	
Pat		11/187240		Notice of Abandonment under 37 CFR 1.53 (f) or (g)	
Pat		10/952500		Updated Filing Receipt	
Pat		10/768692		Notice of Allowance and Fee(s) Due	
Pat		11/177301		Notice of Allowance and Fee(s) Due	
Pat		11/339564		Corrected Filing Receipt	
Pat		11/369839		Corrected Filing Receipt	
Pat		10/623690		Notice Of Abandonment	
Pat		10/025788		Notice Of Abandonment	
Pat		09/942671		Notice Of Abandonment	
Pat		10/680432		Office Action Summary	
Pat		10/510102		Office Action Summary	
Pat		10/754625		Office Action Summary	
Pat		60/791216		Filing Receipt	
Pat		60/784754		Filing Receipt	
Pat		10/564353		Filing Receipt	
Pat		10/540507		Filing Receipt	

Pat 60/789917
Pat 10/359385

Filing Receipt
Notice of Abandonment

[First](#) [Previous](#) [Next](#) [Last](#)

Daily Mail Report for 5/2/2006

Pat	10/197888	advisory action before the filing of and appeal brief
Pat	09762550	advisory action before the filing of and appeal brief
Pat	11/008247	Notice of Allowance and Fee(s) Due
Pat	10/757973	Notice of Allowance and Fee(s) Due
Pat	10/206359	Office Action Summary
Pat	10/997908	Office Action Summary
Pat	10/334795	Office Action Summary
Pat	10/609384	Office Action Summary
Pat	10/893543	Office Action Summary
Pat	10/494241	Office Action Summary
Pat	10/181370	Office Action Summary
Pat	10/609468	Office Action Summary
Pat	11/374157	Office Action Summary
Pat	10/512942	Office Action Summary
Pat	09/956196	Office Action Summary

Other Mail Received:[First](#) [Previous](#) [Next](#) [Last](#)

Daily Mail Report for 5/3/2006

PTO Mail Received:

Delivered	Case Typ	App/Reg No	Cint/Mttr	Action	Atty
	TM	75/869302		Acknowledgment of Request to Withdraw As Attorney of Record	
	TM	78/249647		Notice of Approval of Extension Request	
	TM	75/818089		Acknowledgment of Request to Withdraw As Attorney of Record	
	Pat	10/849152		Office Action Summary	
	Pat	10/787360		Office Action Summary	
	Pat	09/442248		Office Action Summary	
	Pat	10/449609		Office Action Summary	
	Pat	10/384639		Office Action Summary	
	Pat	11/266203		Office Action Summary	
	Pat	10/760346		Office Action Summary	
	Pat	10/942010		Office Action Summary	
	Pat	10/838200		Office Action Summary	
	Pat	10/218587		Office Action Summary	
	Pat	11/326599		Filing Receipt	
	Pat	10/296540		Notice of Abandonment	
	Pat	6467699		NOTICE OF NON-ACCEPTANCE OF PATENT MAINTENANCE FEE	
	TM	74/264374		notice of acceptance of renewal	
	TM	76/555804		Notice of Approval of Extension Request	
	Pat	10/479542		NOTICE OF ALLOWANCE AND FEE (S) DUE	
	Pat	11/008349		NOTICE OF ALLOWANCE AND FEE (S) DUE	
	Pat	10/807428		NOTICE OF ALLOWANCE AND FEE (S) DUE	
	Pat	10/486289		NOTICE OF ALLOWANCE AND FEE (S) DUE	
	Pat	10/967351		NOTICE OF ALLOWANCE AND FEE (S) DUE	
	Pat	10/529150		NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT	
	Pat	11/344130		NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT	
	Pat	11/247598		NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT	
	Pat	10/528191		NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT	
	Pat	09/816896		Letters Patent Received	
	Pat	11/230521		Letters Patent Received	
	Pat	10/829215		Letters Patent Received	
	Pat	10/154855		Letters Patent Received	
	Pat	10/214703		Letters Patent Received	
	Pat	10/823730		Letters Patent Received	
	Pat	10/365618		Letters Patent Received	
	Pat	10/238629		Letters Patent Received	
	Pat	10/739535		Letters Patent Received	
	Pat	09/962123		Letters Patent Received	
	Pat	10/342189		Letters Patent Received	
	Pat	10/164311		Letters Patent Received	

Daily Mail Report for 5/3/2006

Pat	10/439291	Letters Patent Received
Pat	10/274053	Letters Patent Received
Pat	11/082709	Letters Patent Received
Pat	09/910779	Letters Patent Received
Pat	11/078734	Letters Patent Received
Pat	10/601221	Letters Patent Received
Pat	10/492133	Letters Patent Received
Pat	10/793009	Letters Patent Received
Pat	10/784210	Letters Patent Received
Pat	10/307932	Letters Patent Received
Pat	11/206106	Letters Patent Received
Pat	10/500368	Letters Patent Received
Pat	09/147443	Letters Patent Received

Other Mail Received:

Daily Mail Report for 5/4/2006**PTO Mail Received:**

Delivered	Case Typ	App/Reg No	CInt/Mtr	Action	Atty
	TM	78866911		Pseudo Mark	
	TM	78/398490		Notice of Approval of Extension	
				Reqeust	
	Pat	60/794834		Filing Receipt	
	Pat	11/377372		Filing Receipt	
	Pat	PCT/US06/095		Notice concerning Payment of	
		10		Prescribed Fees	
	TM	78/598413		Examiner's Amendment	
	Pat	11/396899		Notice to File Missing Parts of	
				Nonprovisional Application	
	Pat	6416593		cERTIFICATE OF CORRECTION	
	TM	78/529158		Certificate of Registration	
	Pat	29/257144		Notice to Missing Parts of	
				Nonprovisional Application	
	Pat	09/977260		Letters Patent Received	
	Pat	10/858376		Letters Patent Received	
	Pat	11/374156		Corrected filing receipt	
	Pat	08/296182		Notice of accpetance of power of	
				attorney	
	Pat	11/031002		Priority Acknowledgement	
	Pat	09/830011		Notice regarding drawings	
	Pat	11/146083		Notice of Publication of Application`	
	Pat	10/524630		Notice of New or Revised Projected	
				Publication Date	
	Pat	09/578348		OFFICE COMMUNICATION	
	Pat	10/546290		Filing Receipt / Notice of Acceptance	
	Pat	10/072601		NOTICE REGARDING CHANGE	
				OF POWER OF ATTORNEY	
	Pat	10/527991		Notice of New or Revised Projected	
				Publication Date	
	Pat	60/790528		Filing receipt	
	Pat	11/384524		Filing receipt	
	Pat	11/373913		Filing receipt	
	Pat	11/279326		Filing receipt	
	Pat	10/029304		advisory action before the filing of and	
				appeal brief	
	Pat	10/854787		Advisory Action (transferred to	
				Marshall, Gerstein, etc).	
	Pat	10/239657		nOTICE OF ABANDONMENT	
	Pat	10/755317		advisory action before the filing of and	
				appeal brief	
	Pat	10/471450		nOTICE OF ABANDONMENT	
	Pat	10/863521		Notice fo Abandonment	
	Pat	10/902422		NOTICE OF ALLOWANCE	
	Pat	29/233670		Notice of Allowance and Fee(s) Due	
	Pat	10/543810		NOTICE OF RECORDATION OF	
				ASSIGNMENT DOCUMENT	
	Pat	10/728895		nOTICE OF ALLOWANCE	

Pat pct/US2006/00
9458

NOTIFICATION CONCERNING
PAYMENT OF PRESRCIBED FEES

First Previous Next Last

Daily Mail Report for 5/4/2006

Pat	pct/US2006/00 9459	nOTIFICATION CONCERNING PAYMENT OF PRESCRIBDE FEES
Pat	11/402255	Notice of Missing Parts & Filing Receipt
Pat	11/377646	Notice of Missing Parts & Filing Receipt
Pat	29/257145	Notice of Missing Parts & Filing Receipt
TM	78/733850	oFFICE ACTION
Pat	11/344128	NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT
Pat	09/853033	Supplementary Notice of Allowability
Pat	11/004860	NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT
Pat	10/195101	nOTICE OF ABANDONMENT
Pat	11/210789	NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT
Pat	PCT/US03/220 19	inVITATION TO PAY ADDITIONAL FEES
Pat	11/347299	NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT
Pat	10/540855	nOTICE OF ALLOWANCE
Pat	11/337580	NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT
Pat	11/212101	NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT
Pat	11/252986	NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT
Pat	10/544022	NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT
Pat	11/345240	NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT
Pat	10/543593	NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT
Pat	11/347365	NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT
Pat	10/544029	NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT
Pat	60/794102	fILING RECEIPT
Pat	10/350376	Office Action Summary
Pat	09/257209	Office Action Summary
Pat	10/947287	Office Action Summary
Pat	10/095298	advisory action before the filing of and appeal brief
Pat	10/031145	Office Action Summary
Pat	11/386836	notice to comply with requirements for application containing sequence disclosures
Pat	10/129003	Office Action Summary
Pat	10/694992	Office Action Summary

Pat	09/903621	Office Action Summary
Pat	11/392956	Notice of Missing Parts & Filing Receipt
Pat	10/478245	Office Action Summary
Pat	10/704123	Notice of allowance
Pat	10/807737	Office Action Summary
Pat	11/070444	Notice of abandonment

[First](#) [Previous](#) [Next](#) [Last](#)

Daily Mail Report for 5/4/2006

Pat	11/133177	Office Action Summary
Pat	10/550271	FILING RECEIPT/NOTICE OF ACCEPTANCE OF APPLICATION UNDER 35 U.S.C 371 AND 37 CFR 1.495
Pat	10/368348	Office Action Summary
Pat	10/548572	Notice of New or Revised projected Publication Date
Pat	10/454795	Office Action Summary
Pat	10/541460	Notice of New or Revised projected Publication Date
Pat	10/520127	Notice of New or Revised projected Publication Date
Pat	10/563614	Notice of New or Revised projected Publication Date
Pat	10/563602	Notice of New or Revised projected Publication Date
Pat	11/252611	Notice of Publication of Application`
Pat	10/078383	Office Action Summary
Pat	11/253759	Notice of Publication of Application`
Pat	11/143486	Office Action Summary
Pat	11/251762	Notice of Publication of Application`
Pat	11/209039	Notice of Publication of Application`
Pat	11/252619	Notice of Publication of Application`
Pat	11/176667	Notice of Publication of Application`
Pat	11/226353	Notice of Publication of Application`
Pat	11/536310	Notice of Publication of Application`
Pat	11/249736	Notice of Publication of Application`
Pat	10/946622	Notice of Publication of Application`
Pat	10/467397	Office Action Summary
Pat	11/032004	Notice of Publication of Application`
Pat	10/968270	Notice of Publication of Application`
Pat	10/048023	Office Action Summary
Pat	11/249337	Notice of Publication of Application`
Pat	11/253760	Notice of Publication of Application`
Pat	11/236841	Notice of Publication of Application`
Pat	11/001156	Office Action Summary
Pat	10/525321	Notice of Publication of Application`
Pat	11/236826	Notice of Publication of Application`
Pat	11/249451	Notice of Publication of Application`
Pat	10/503655	Office Action Summary
Pat	10/797031	Office Action Summary

[First](#) [Previous](#) [Next](#) [Last](#)

Daily Mail Report for 5/4/2006

Pat	10/384743	Office Action Summary
Pat	09/770089	Office Action Summary
Pat	11/050437	Office Action Summary
Pat	10/530186	Office Action Summary
Pat	10/897126	Office Action Summary
Pat	10/670270	Office Action Summary
Pat	10/456395	Office Action Summary
Pat	11/082198	Office Action Summary
Pat		Office Action Summary
Pat	10/997904	Office Action Summary
Pat	09/812816	Office Action Summary
Pat	10/862470	Office Action Summary
Pat	10/507117	Office Action Summary
Pat	10/863905	Office Action Summary
Pat	10/451947	Office Action Summary
Pat	10/209974	Interview Summary
Pat	10/563578	Notice of New or Revised projected Publication Date
Pat	10/968284	NOTICE OF PUBLICATION OF APPLCATION
Pat	11/246136	NOTICE OF PUBLICATION OF APPLCATION
Pat	11/248185	NOTICE OF PUBLICATION OF p APPLCATION
Pat	11/250609	NOTICE OF PUBLICATION OF APPLCATION
Pat	11/226462	NOTICE OF PUBLICATION OF APPLCATION
Pat	10/508781	NOTICE OF PUBLICATION OF APPLCATION
Pat	11/252542	NOTICE OF PUBLICATION OF APPLCATION
Pat	11/246310	NOTICE OF PUBLICATION OF APPLCATION
Pat	11/248003	NOTICE OF PUBLICATION OF APPLCATION
Pat	10/535703	NOTICE OF PUBLICATION OF APPLCATION
Pat	11/248609	NOTICE OF PUBLICATION OF APPLCATION
Pat	11/077362	NOTICE OF PUBLICATION OF APPLCATION
Pat	11/244326	NOTICE OF PUBLICATION OF APPLCATION
Pat	11/237884	NOTICE OF PUBLICATION OF APPLCATION
Pat	10/968034	NOTICE OF PUBLICATION OF APPLCATION
Pat	11/239465	NOTICE OF PUBLICATION OF APPLCATION

Pat	10/968271	NOTICE OF PUBLICATION OF APPLCATION
Pat	11/230542	NOTICE OF PUBLICATION OF APPLCATION
Pat	11/253809	NOTICE OF PUBLICATION OF APPLCATION
Pat	10/964819	NOTICE OF PUBLICATION OF APPLCATION

[First](#) [Previous](#) [Next](#) [Last](#)

Daily Mail Report for 5/4/2006

Pat	11/249450	NOTICE OF PUBLICATION OF APPLCATION
Pat	11/244404	NOTICE OF PUBLICATION OF APPLCATION
Pat	11/292107	NOTICE OF PUBLICATION OF APPLCATION

Other Mail Received:[First](#) [Previous](#) [Next](#) [Last](#)

Daily Mail Report for 5/5/2006**PTO Mail Received:**

Delivered	Case Typ	App/Reg No	CInt/Mttr	Action	Atty
	Pat	10/795279		Office Communication	
	Pat	10/398900		Letter of Patents	
	Pat	10/734577		Notice of Abandonment	
	Pat	09/914270		Notice of Abandonment	
	Pat	09/936869		Notice of Non-Recordation of Document	
	Pat	11/059411		Notice of Allowance and Fee(s) Due	
	Pat	09/578348		OFFICE COMMUNICATION	
	Pat	11/327596		Updated filing receipt	
	Pat	10/771276		Advisory Action	
	TM	74/527349		notice of acceptance of renewal	
	Pat	10/714643		Notice of Acceptance of POA	
	Pat	11/016983		Notice of Abandonment	
	Pat	10/392383		Notice of Abandonment	
	Pat	11/059409		Notice of Allowance and Fee(s) Due	
	Pat	10/474422		Notice of Non -Responsive Amendment	
	Pat	10/300739		Notice of Allowance and Fee(s) Due	
	Pat	10/768736		Office Action Summary	
	TM	78/388873		Office Action	
	Pat	10/814294		Office Action Summary	
	Pat	10/755318		interview summary	
	Pat	10/610770		Office Action Summary	
	Pat	10/546866		NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENTQ	
	Pat	11/392676		NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENTQ	
	Pat	10/396473		NOTICE OF ALLOWANCE AND FEE (S) DUE	
	Pat	10/509126		NOTICE OF ALLOWANCE AND FEE (S) DUE	
	Pat	10/918357		Office Action Summary	
	Pat	10/323736		Office Action Summary	
	Pat	10/758315		Office Action Summary	
	Pat	10/235848		Office Action Summary	
	Pat	09/978539		Office Action Summary	
	Pat	10/442107		Office Action Summary	
	Pat	10/602021		Office Action Summary	
	Pat	11/268617		Office Action Summary	
	Pat	10/671883		Office Action Summary	
	Pat	10/673038		Office Action Summary	
	TM	76/378028		Notice of Acceptance of Statement of Use	
	Pat	10/788414		Office Action Summary	
	Pat	5739013		Notice of Non-Acceptance of Patent	
				Manintenace Fee	
	Pat	08/614150		Notice of Patent Expiration	
	Pat	09/462788		Notice of Patent Expiration	

[First](#) [Previous](#) [Next](#) [Last](#)

Daily Mail Report for 5/5/2006

Pat	08/672261	Maintenance Fee Reminder
Pat	08/418111	Maintenance Fee Reminder
Pat	08/773951	Maintenance Fee Reminder
Pat	08/919706	Maintenance Fee Reminder
Pat	09/920856	Maintenance Fee Reminder
Pat	09/920857	Maintenance Fee Reminder
Pat	09/612302	Maintenance Fee Reminder
Pat	08/889599	Maintenance Fee Statement
Pat	09/272171	Maintenance Fee Statement
Pat	08/773325	Maintenance Fee Statement
Pat	09/148701	Maintenance Fee Statement
Pat	09/621349	Maintenance Fee Statement
Pat	08/715375	Maintenance Fee Statement
Pat	08/973470	Maintenance Fee Statement
Pat	09/426952	Maintenance Fee Statement
Pat	08/745200	Maintenance Fee Statement
Pat	09/667099	Maintenance Fee Statement
Pat	09/533776	Maintenance Fee Statement
Pat	09/521221	Maintenance Fee Statement
Pat	08/865658	Maintenance Fee Statement
Pat	09/691062	Maintenance Fee Statement
Pat	09/307741	Maintenance Fee Statement
Pat	08/687627	Maintenance Fee Statement
Pat	09/477359	Maintenance Fee Statement
Pat	09/157566	Maintenance Fee Statement
Pat	09/096193	Maintenance Fee Statement
Pat	09/782273	Maintenance Fee Statement
Pat	09/593128	Maintenance Fee Statement
Pat	08/706334	Maintenance Fee Statement
Pat	10/124394	Maintenance Fee Statement
Pat	09/670010	Maintenance Fee Statement
Pat	08/835478	Maintenance Fee Statement
Pat	09/880894	Maintenance Fee Statement
Pat	09/855534	Maintenance Fee Statement
Pat	09/731985	Maintenance Fee Statement
Pat	09/971183	Maintenance Fee Statement
Pat	09/792973	Maintenance Fee Statement
Pat	09/812819	Maintenance Fee Statement
Pat	09/693845	Maintenance Fee Statement
Pat	08/826134	Maintenance Fee Statement
Pat	09/899920	Maintenance Fee Statement
Pat	08/493117	Maintenance Fee Statement

Other Mail Received:[First](#) [Previous](#) [Next](#) [Last](#)

Daily Mail Report for 5/7/2006**PTO Mail Received:**

Delivered	Case Typ	App/Reg No	CInt/Mttr	Action	Atty
Pat		11/407357		Notice of Missing Parts & Filing Receip	

Other Mail Received:

Daily Mail Report for 5/8/2006**PTO Mail Received:**

Delivered	Case Typ	App/Reg No	CInt/Mttr	Action	Atty
Pat		11/169802		Decision Granting Petition Under 37 cfr 1.313 (c)(2)	
Pat		60/785363		Filing Receipt	
Pat		10/471835		Interweiw Summary	
Pat		PCT/US2006/0		NOTIFICATION CONCERNING PAYMENT OF PRESRCIBED FEES	
		09837			
Pat		09/728321		Notice of Patent Expiration	
Pat		09/398997		Notice of Patent Expiration	
Pat		09/470946		Notice of Patent Expiration	
Pat		09/709472		Notice of Patent Expiration	
Pat		09/196736		Maintenance Fee Statement	
Pat		08/977623		Maintenance Fee Statement	
Pat		09/983753		Maintenance Fee Statement	
Pat		08/696103		Maintenance Fee Statement	
Pat		09/903986		Maintenance Fee Reminder	
Pat		09/718093		Maintenance Fee Reminder	
Pat		07/879110		Maintenance Fee Reminder	
Pat		09/424888		Maintenance Fee Reminder	
Pat		09/835640		Maintenance Fee Reminder	
Pat		08/776575		Maintenance Fee Reminder	
Pat		08/816519		Maintenance Fee Reminder	
Pat		08/861269		Maintenance Fee Reminder	
Pat		60/794836		Filing Receipt	
Pat		60/794835		Filing Receipt	
Pat		11/412209		Filing Receipt	
Pat		11/279463		Filing Receipt	
Pat		10/402834		Filing Receipt	
Pat		60/794858		Filing Receipt	
Pat		60/794838		Filing Receipt	
Pat		60/743988		Filing Receipt	
Pat		11/400795		Filing Receipt	
Pat		60/795179		Filing Receipt	
Pat		10/546172		Filing Receipt	
Pat		11/398597		Filing Receipt	
Pat		11/399466		Filing Receipt	
Pat		11/412972		Filing Receipt	
Pat		11/388205		Filing Receipt	
Pat		PCT/US2005/0		NOTIFICATION CONCERNING PAYMENT OF PRESRCIBED FEES	
		13210			
Pat		10/715371		Notice of Allowance and Fee(s) Due	
Pat		11/104614		Notice of Allowance and Fee(s) Due	
Pat		10/823622		Notice of Allowance and Fee(s) Due	
Pat		10/528564		Notice of Allowance and Fee(s) Due	
Pat		11/242948		Notice of Allowance and Fee(s) Due	

[First](#) [Previous](#) [Next](#) [Last](#)

Daily Mail Report for 5/8/2006

Pat	10/549197	Notice of Acceptance of Application Under 35 U.S.C. 371 AND 37 CFR 1.495
Pat	11/369940	Corrected Filing Receipt
Pat	10/950817	Office Action Summary
TM	76/381543	Notice of Approval of Extension Request
Pat	11/396548	Filing receipt
Pat	11/396547	Filing receipt
Pat	11/395210	Filing receipt
Pat	60/794837	Filing receipt
Pat	10/380623	Office Action Summary
Pat	60/794821	Filing receipt
Pat	11/389155	Filing receipt
Pat	10/547290	Notification of Missing Requirements Under 35 U.S.C 371
Pat	11/389019	Filing receipt
Pat	11/389021	Filing receipt
Pat	11/345266	Notice of Recordation of Assignment Document
Pat	11/401966	Filing receipt
Pat	10/565208	notification of missing requirements under 35 U.S.C 371
Pat	10/546652	notification of missing requirements under 35 U.S.C 371
Pat	11/386937	notice to comply with requirements for application containing sequence disclosures
Pat	11/407888	notice to comply with requirements for application containing sequence disclosures
Pat	10/549317	notification to comply with requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures
Pat	11/403207	Notice of Missing Parts & Filing Receipt
Pat	11/397963	Notice of Missing Parts & Filing Receipt
Pat	11/402259	Notice of Missing Parts & Filing Receipt
Pat	11/402256	Notice of Missing Parts & Filing Receipt
Pat	11/396911	Notice of Missing Parts & Filing Receipt
Pat	29/256410	Notice of Missing Parts & Filing Receipt
TM	78/642160	Notice of Publication Under 12@
Pat	10/151883	Notice of abandonment

TM	78/445660	Acknowledgement of Request to Withdraw As Attorney of Record
Pat	pct/us2003/002	Written Opinion
	340	
Pat	pct/us2005/014	NOTIFICATION CONCERNING
	032	PAYMENT OF PRESRCIBED FEES
Pat	78/471179	Notice of Approval of Extension
		Request

[First](#) [Previous](#) [Next](#) [Last](#)

Daily Mail Report for 5/8/2006

Pat	79/009609	notice of publication under 12(a)
Pat	10/485276	Office Action Summary
Pat	10/381462	Office Action Summary
Pat	10/777288	Office Action Summary
Pat	10/935271	Office Action Summary
Pat	10/384766	Office Action Summary
Pat	10/446704	advisory action before the filing of and appeal brief
Pat	10/482110	Office Action Summary
Pat	10/521963	Office Action Summary
Pat	10/232839	Notice of allowance
Pat	11/115397	Office Action Summary
Pat	10/673647	Office Action Summary
Pat	10/258803	Notice of allowance
Pat	10/762556	Office Action Summary
Pat	10/140293	Notice of allowance
Pat	10/755382	Office Action Summary
Pat	10/059412	Notice of allowance
Pat	10/734638	Office Action Summary
Pat	11/014135	Office Action Summary
Pat	10/397411	Notice of allowance
Pat	11/003011	Office Action Summary
Pat	10/763418	Office Action Summary
Pat	10/968004	Notice of allowance
Pat	10/995344	Office Action Summary
Pat	10/279099	Office Action Summary
Pat	10/254783	Office Action Summary
Pat	09/857600	Office Action Summary
Pat	10/277928	Office Action Summary
Pat	10/012509	Office Action Summary
Pat	11/008299	Office Action Summary
Pat	11/008294	Office Action Summary
Pat	08/593575	Notice of Patent Expiration
Pat	09/413876	Notice of Patent Expiration
Pat	08/783700	Notice of Patent Expiration
Pat	08/943413	Maintance Fee Reminder
Pat	08/788299	Maintance Fee Reminder
Pat	08/844759	Maintance Fee Reminder
Pat	08/801199	Maintance Fee Reminder
Pat	08/710860	Maintance Fee Reminder
Pat	07/956861	Maintance Fee Reminder
Pat	08/527452	Maintance Fee Reminder
Pat	09/691101	Maintance Fee Reminder
Pat	08/496910	Maintance Fee Reminder
Pat	09/622007	Maintance Fee Reminder
Pat	07/948487	Maintance Fee Reminder
Pat	08/781811	Maintance Fee Reminder
Pat	09/997522	Notice of abandonment
Pat	10/474949	Notice of abandonment
Pat	08/824610	Maintenance Fee Statement

Pat 08/629038
Pat 08/928435

Maintenance Fee Statement
Maintenance Fee Statement

[First](#) [Previous](#) [Next](#) [Last](#)

Daily Mail Report for 5/8/2006

Pat		
Pat	08/928435	Maintenance Fee Statement
Pat	08/404871	Maintenance Fee Statement
Pat	09/424879	Maintenance Fee Statement
Pat	09/606188	Maintenance Fee Statement
Pat	09/615056	Maintenance Fee Statement
Pat	09/669689	Maintenance Fee Statement
Pat	09/691238	Maintenance Fee Statement
Pat	08/624056	Maintenance Fee Statement
Pat	09/831365	Maintenance Fee Statement
Pat	08/900491	Mainetnance Fee Reminder
Pat	09/446616	Mainetnance Fee Reminder
Pat	08/848831	Mainetnance Fee Reminder
Pat	09/880894	Mainetnance Fee Reminder
Pat	08/743819	Mainetnance Fee Reminder
Pat	08/733917	Notice of patent expiration
Pat	09/673413	Maintenance fee statement
Pat	09/628686	Maintenance fee statement
Pat	09/717252	Maintenance fee statement
Pat	09/855704	Maintenance fee statement
Pat	09/725275	Maintenance fee statement
Pat	09/862444	Maintenance fee statement
Pat	09/719636	Maintenance fee statement
Pat	09/843843	Maintenance fee statement
Pat	09/923170	Maintenance fee statement
Pat	09/487875	Maintenance fee statement
Pat	09/924825	Maintenance fee statement
Pat	08/876479	Maintenance fee statement
Pat	09/556957	Maintenance fee statement
Pat	09/594613	Maintenance fee statement

Other Mail Received:[First](#) [Previous](#) [Next](#) [Last](#)

Daily Mail Report for 5/9/2006**PTO Mail Received:**

Delivered	Case Typ	App/Reg No	CInt/Mttr	Action	Atty
	Pat	10/530207		notice of acceptance of application under 35 U.S.C. 371 and 37 CFR 1.495	
	TM	1979761		Post Registration Office Action	
	TM	78/741525		Notice of Suspension	
	TM	78/445660		Acknowledgement of Request to Withdraw As Attorney of Record	
	TM	76/548668		Office Action	
	Pat	10/401691		Issue Notification	
	Pat	10/844580		Supplemental Notice of Allowability	
	Pat	PCT/US03/374		Written Opinion	
		12			
	Pat	11/349912		Notice of Recordation of assignment document	
	Pat	10/747960		nOTICE OF ALLOWANCE	
	Pat	10/566996		Notice of Recordation of assignment document	
	Pat	10/510951		Notice of Recordation of assignment document	
	Pat	10/258804		nOTICE OF ALLOWANCE	
	Pat	11/274477		Notice of Recordation of assignment document	
	Pat	10/922941		nOTICE OF ALLOWANCE	
	Pat	11/350083		Notice of Recordation of assignment document	
	Pat	10/644067		Office action summary	
	Pat	11/350128		Notice of Recordation of assignment document	
	Pat	10/654129		Office action summary	
	Pat	10/106876		Office action summary	
	Pat	11/010578		Office action summary	
	Pat	10/523530		Office action summary	
	Pat	11/045343		Office action summary	
	Pat	10/627745		Issue notification	
	Pat	11/401326		filing recipet	
	Pat	09/483205		Notice of acceptance of power of attorney	
	Pat	09/540890		Issue notification	
	Pat	10/042746		Issue notification	
	Pat	10/629705		Issue notification	
	Pat	10/512485		Issue notification	
	Pat	09/627421		Issue notification	
	Pat	10/782938		Issue notification	
	Pat	09/325705		Issue notification	
	Pat	10/624485		Issue notification	
	Pat	09/766675		Issue notification	
	Pat	29/223089		Issue notification	
	Pat	10/873300		Issue notification	
	Pat	10/607272		Issue notification	

Pat	29/221144	Issue notification
Pat	29/221103	Issue notification
Pat	10/512485	Issue notification

[First](#) [Previous](#) [Next](#) [Last](#)

Daily Mail Report for 5/9/2006

Pat	10/942906	Issue notification
Pat	10/244514	Issue notification
Pat	10/954485	Issue notification
Pat	10/614344	Notice Regarding Change of Power of Attorney
Pat	10/614344	Decision on Petition to Withdraw from Record
Pat	10/009570	Interview Summary
Pat	11/079521	Notice of Abandonment under 37 CFR 1.53 (f) or (g)
Pat	10/816933	Notice of Allowance and Fee(s) Due
Pat	10/606123	Notice of Allowance and Fee(s) Due
Pat	11/397810	Filing Receipt
Pat	60/788043	Filing Receipt
Pat	60/788042	Filing Receipt
Pat	11/401002	Filing Receipt
Pat	11/359528	Corrected Filing Receipt
Pat	10/533396	Corrected Filing Receipt
Pat	09/723767	Issue Notification
Pat	10/940645	Issue Notification
Pat	10/450252	Issue Notification
Pat	10/770532	Issue Notification
Pat	09/875529	Issue Notification
Pat	10/481515	Issue Notification
Pat	10/127558	Issue Notification
Pat	11/033451	Issue Notification
Pat	10/944402	Issue Notification
Pat	29/223090	Issue Notification
Pat	11/397902	Notice to File Missing Parts of Non- Provisional Application
Pat	11/405013	Notice to File Missing Parts of Non- Provisional Application
Pat	11/400796	Notice to File Missing Parts of Non- Provisional Application
Pat	09/840787	Notice of Abandonment
Pat	09/855533	Issue Notification
Pat	10/941993	Issue Notification
Pat	10/293208	Issue Notification
Pat	29/218492	Issue Notification
Pat	09/859887	Issue Notification
Pat	09/876082	Issue Notification
Pat	10/025769	Issue Notification
Pat	10/818178	Issue Notification
Pat	10/901378	Issue Notification
Pat	11/401967	filling receipt
Pat	11/401950	filling receipt
Pat	11/396636	filling recipet
Pat	10/031204	Corrected Filing Receipt
Pat	10/547931	Notification of Missing Requirements Under 35 U.S.C. 371 in the U.S.

[First](#) [Previous](#) [Next](#) [Last](#)

Daily Mail Report for 5/9/2006

Pat	10/564745	Notification of Missing Requirements Under 35 U.S.C. 371 in the U.S.
Pat	11/411950	Notice to File Missing Parts of Non- Provisional Application

Other Mail Received:[First](#) [Previous](#) [Next](#) [Last](#)

Daily Mail Report for 5/10/2006**PTO Mail Received:**

Delivered	Case Typ	App/Reg No	CInt/Mttr	Action	Atty
	Pat	10/621570		Notice of Allowability	
	Pat	PCT/US04/179		Written Opinion of The International	
		65		Searching Authority	
	Pat	PCT/US04/179		Notification of Transmittal of the	
		65		Internltional Search Report and the	
				Written Opinion	
	Pat	11/350756		notice of recordation of assignemnt	
				document	
	Pat	10/394179		NOTICE OF ALLOWANCE AND	
				FEE (S) DUE	
	Pat	09/984884		NOTICE OF ALLOWANCE AND	
				FEE (S) DUE	
	Pat	10/913510		Office Action Summary	
	Pat	11/350074		notice of recordation of assignemnt	
				document	
	Pat	10/295820		Office Action Summary	
	Pat	11/051474		Office Action Summary	
	Pat	11/080834		Office Action Summary	
	Pat	11/033176		Office Action Summary	
	Pat	10/548734		notice of recordation of assignemnt	
				document	
	Pat	10/769920		Office Action Summary	
	Pat	11/080843		Office Action Summary	
	Pat	10/993512		Office Action Summary	
	Pat	10/275695		Office Action Summary	
	Pat	11/080844		Office Action Summary	
	Pat	10/953365		Office Action Summary	
	Pat	10/536694		Office Action Summary	
	Pat	11/248150		notice of recordation of assignemnt	
				document	
	Pat	10/564515		notice of recordation of assignemnt	
				document	
	Pat	11/127289		Letters of patent	
	Pat	10/964829		Letters of Patent	
	Pat	10/132385		Letters of Patent	
	Pat	10/632805		Letters of Patent	
	Pat	10/405629		Letters of Patent	
	Pat	10/806468		Letters of Patent	
	Pat	10/828436		Letters of Patent	
	Pat	10/935399		Letters of Patent	
	Pat	10/389953		Letters of Patent	
	Pat	10/679868		Letters of Patent	
	Pat	10/064064		Letters of Patent	
	Pat	10/777137		Letters of Patent	
	Pat	10/648826		Letters of Patent	
	Pat	10/637642		Letters of Patent	
	Pat	11/008124		Letters of Patent	
	Pat	10/826406		Letters of Patent	

Pat	10/662442	Letters of Patent
Pat	10/093637	Letters of Patent
Pat	10/052777	Letters of Patent
Pat	10/031346	Letters of Patent

[First](#) [Previous](#) [Next](#) [Last](#)

Daily Mail Report for 5/10/2006

Pat	10/024051	Letters of Patent
Pat	10/864551	Letters of Patent
Pat	10/512426	Letters of Patent
Pat	10/388492	Letters of Patent
Pat	11/005482	Letters of Patent
Pat	10/419950	Letters of Patent
Pat	09/988012	Letters of Patent
Pat	10/473410	Letters of Patent
Pat	29/197924	Letters of Patent
Pat	10/321396	Letters of Patent
TM	78/425607	Notice of Acceptance of SOU
TM	78/474897	Notice of Approval of Extension Request
TM	78/318072	Notice of Approval of Extension Request

Other Mail Received:[First](#) [Previous](#) [Next](#) [Last](#)

Daily Mail Report for 5/11/2006**PTO Mail Received:**

Delivered	Case Typ	App/Reg No	CInt/Mttr	Action	Atty
	TM	78/214689		extension of time to oppose	
	Pat	10/250668		Office Communication	
	Pat	10/902061		Supp Notice of Allowability	
	Pat	09/972245		NOTICE OF PANEL DECISION FROM PRE-APEAL BRIEF REVIEW	
	Pat	10/775133		Priorty Acknowledgement	
	Pat	10/820016		Letter Of Patent	
	Pat	11/398763		Notice of Missing Parts & Filing Receip	
	Pat	10/549284		notice of acceptance of application under 35 U.S.C. 371 AND 37 CFR 1.495 & filing receipt	
	Pat	09/570186		Notice of Abondoment	
	Pat	10/344702		Notice fo Abandonment	
	Pat	10/743491		Advisory Action Before Filing of Appeal Brief	
	Pat	10/866693		Advisory Action Before Filing of Appeal Brief	
	Pat	10/806354		Advisory Action Before Filing of Appeal Brief	
	Pat	11/349914		Office action summary	
	Pat	10/960501		Office action summary	
	Pat	10/282490		Notice of allowance	
	Pat	10/985994		Notice of allowance	
	Pat	11/322273		Corrected filing receipt	
	Pat	11/087663		Letter of Patent	
	Pat	11/376436		filing recipet	
	Pat	60/744482		filing recipet	
	Pat	60/784753		filing recipet	
	Pat	11/361055		Updated Filiing Receipt	
	Pat	11/303016		Updated Filiing Receipt	
	Pat	10/488259		Notice of allowance	
	Pat	10/682846		Notice of allowance	
	Pat	10/028732		Notice of allowance	
	Pat	11/405700		Notice of Missing Parts & Filing Receip	
	Pat	11/405697		Notice of Missing Parts & Filing Receip	
	Pat	11/402257		Notice of Missing Parts & Filing Receip	
	Pat	11/394202		Notice of Missing Parts & Filing Receip	
	Pat	11/416065		Notice of Missing Parts & Filing Receip	
	Pat	11/402264		Notice of Missing Parts & Filing Receip	
	Pat	11/386082		Notice of Missing Parts & Filing Receip	

TM 78/738840

Pat 09/582211

Pat 10/509738

Office Action

mAINTENANCE FEES

STATEMENT

Office Action Summary

First Previous Next Last

Daily Mail Report for 5/11/2006

Pat	11/079386	Office Action Summary
Pat	10/747961	Office Action Summary
Pat	10/727535	Office Action Summary
Pat	10/474425	Office Action Summary
Pat	11/030958	Office Action Summary
Pat	10/631845	Office Action Summary
Pat	10/702619	Office Action Summary
Pat	10/451254	Office Action Summary
Pat	10/3174761	Notice of Non-Recordation of Document
Pat	PCT/US2006/010182	NOTIFICATION CONCERNING PAYMENT OF PRESRCIBED FEES
Pat	10/218906	Interview Summary
Pat	10/688881	Decision on Application for Patent Term Adjustment
Pat	10/522777	Decision on Petition Under 37 CFR 1.47 (a)
Pat	10/644042	Office Communcation
Pat	11/125315	Advisory Action Before the Filing of an Appeal Brief
Pat	11/198402	Notice of Abandonment under 37 CFR 1.53 (f) or (g)
Pat	09/459419	Notice of Abandonment
Pat	11/044630	Office Action Summary
Pat	10/658203	Office Action Summary
Pat	11/401262	filling receipt
Pat	11/401958	filling recipet
Pat	60/792951	filling recipet
Pat	60/789160	filling recipet
Pat	10/563575	notice of recordation of assignemnt document
Pat	10/564966	notice of recordation of assignemnt document
Pat	10/528563	notice of recordation of assignemnt document
Pat	10/567139	notice of recordation of assignemnt document

Other Mail Received:[First](#) [Previous](#) [Next](#) [Last](#)

Daily Mail Report for 5/12/2006**PTO Mail Received:**

Delivered	Case Typ	App/Reg No	CInt/Mttr	Action	Atty
	Pat	29/257143		Notice of Missing Parts & Filing Receipt	
	Pat	10/471009		decision granting pta request	
	TM	79/012098		Notice of Publication Under 12@	
	Pat	11/354135		Notice of Recordation OF ASSIGNMENT DOCUMENT	
	Pat	10/567829		Notice of Recordation OF ASSIGNMENT DOCUMENT	
	Pat	10/568290		Notice of Recordation OF ASSIGNMENT DOCUMENT	
	Pat	11/239355		Notice of Recordation OF ASSIGNMENT DOCUMENT	
	Pat	11/349914		Notice of Recordation OF ASSIGNMENT DOCUMENT	
	Pat	11/349919		Notice of Recordation OF ASSIGNMENT DOCUMENT	
	Pat	10/880593		Office Action Summary	
	Pat	10/761918		Office Action Summary	
	Pat	09/750287		Office Action Summary	
	Pat	10/468221		Office Action Summary	
	Pat	11/353218		Office Action Summary	
	Pat	09/973835		Office Action Summary	
	Pat	10/621320		Office Action Summary	
	Pat	11/005296		Office Action Summary	
	Pat	10/482379		Office Action Summary	
	TM	76/561719		Acknowledgement of Request to Withdraw As Attorney of Record	
	TM	76/561769		Acknowledgement of Request to Withdraw As Attorney of Record	
	TM	76/593864		Acknowledgement of Request to Withdraw As Attorney of Record	
	TM	76/593865		Acknowledgement of Request to Withdraw As Attorney of Record	
	TM	76/562007		Acknowledgement of Request to Withdraw As Attorney of Record	
	TM	78/337251		Acknowledgement of Request to Withdraw As Attorney of Record	
	TM	78/337216		Acknowledgement of Request to Withdraw As Attorney of Record	
	TM	92042327		Bose Corporation v. Custom Electronic Design	

Other Mail Received:

Bibliographic Data

Application Number:	10/553,904	Customer Number:	22428
Filing or 371 (c) Date:	-	Status:	Application Undergoing Preexam Processing
Application Type:	Utility	Status Date:	11-02-2005
Examiner Name:	-	Location:	ELECTRONIC
Group Art Unit:	1651	Location Date:	-
Confirmation Number:	7961	Earliest Publication No:	-
Attorney Docket Number:	053694-0131	Earliest Publication Date:	-
Class / Subclass:	424/	Patent Number:	-
First Named Inventor:	Lars Bjorck , Lund, (SE)	Issue Date of Patent:	-

Title of Invention: Method and treatment

[Close Window](#)

Transaction History

Date	Transaction Description
03-29-2006	Additional Application Filing Fees
03-29-2006	Information Disclosure Statements
03-29-2006	Drawing Preliminary Amendment
04-27-2006	Sequence disclosure problems
04-11-2006	Cleared by OIPE CSR
04-11-2006	Cleared by OIPE CSR
10-21-2005	Initial Exam Team nn

[Close Window](#)

This application is officially maintained in electronic form. To View: Click the desired Document Description. To Download and Print: Check the desired document(s) and click Start Download.

Available Documents

Mail Room Date	Document Description	Document Category	Page Count
11-20-2006	Pre-Exam Formalities Notice	PROSECUTION	3
07-17-2006	Applicant Response to Pre-Exam Formalities Notice	PROSECUTION	2
07-17-2006	Oath or Declaration filed	PROSECUTION	10
03-29-2006	Miscellaneous Internal Document	PROSECUTION	1
03-29-2006	Application Data Sheet	PROSECUTION	5
03-29-2006	Miscellaneous Incoming Letter	PROSECUTION	2
03-29-2006	Oath or Declaration filed	PROSECUTION	16
03-29-2006	Information Disclosure Statement (IDS) Filed	PROSECUTION	4
03-29-2006	Foreign Reference	PRIOR ART	56
03-29-2006	Foreign Reference	PRIOR ART	42
03-29-2006	Foreign Reference	PRIOR ART	94
03-29-2006	Foreign Reference	PRIOR ART	92
03-29-2006	NPL Documents	PRIOR ART	11
03-29-2006	NPL Documents	PRIOR ART	6
03-29-2006	NPL Documents	PRIOR ART	13
03-29-2006	NPL Documents	PRIOR ART	6
03-29-2006	NPL Documents	PRIOR ART	15
03-29-2006	NPL Documents	PRIOR ART	11
03-29-2006	NPL Documents	PRIOR ART	14
03-29-2006	NPL Documents	PRIOR ART	8
03-29-2006	NPL Documents	PRIOR ART	8
03-29-2006	NPL Documents	PRIOR ART	5
03-29-2006	NPL Documents	PRIOR ART	7
03-29-2006	NPL Documents	PRIOR ART	8
03-29-2006	NPL Documents	PRIOR ART	6
03-29-2006	NPL Documents	PRIOR ART	5
03-29-2006	NPL Documents	PRIOR ART	18
03-29-2006	NPL Documents	PRIOR ART	10
10-21-2005	Miscellaneous Internal Document	PROSECUTION	1
10-21-2005	Fee Worksheet (PTO-875)	PROSECUTION	1
10-21-2005	Fee Worksheet (PTO-875)	PROSECUTION	1
10-21-2005	Claims Worksheet (PTO-2022)	PROSECUTION	1
10-21-2005	Transmittal of New Application	PROSECUTION	2
10-21-2005	Specification	PROSECUTION	40
10-21-2005	Claims	PROSECUTION	4
10-21-2005	Abstract	PROSECUTION	1
10-21-2005	Drawings	PROSECUTION	6
10-21-2005	Sequence Listing	PROSECUTION	14
10-21-2005	Miscellaneous Internal Document	PROSECUTION	1
10-21-2005	Fee Worksheet (PTO-875)	PROSECUTION	1
10-21-2005	Preliminary Amendment	PROSECUTION	1
10-21-2005	Claims	PROSECUTION	4
10-21-2005	Applicant Arguments/Remarks Made in an Amendment	PROSECUTION	1
10-21-2005	Certified Copy of Foreign Priority Application	PROSECUTION	69
10-21-2005	Certified Copy of Foreign Priority Application	PROSECUTION	81
10-21-2005	Application Data Sheet	PROSECUTION	5
10-21-2005	Documents submitted with 371 Applications	PROSECUTION	65
10-21-2005	Documents submitted with 371 Applications	PROSECUTION	7

[Close Window](#)

Bibliographic Data

Application Number:	10/553,904	Customer Number:	22428
Filing or 371 (c) Date:	-	Status:	Application Undergoing Preexam Processing
Application Type:	Utility	Status Date:	11-02-2005
Examiner Name:	-	Location:	ELECTRONIC
Group Art Unit:	1651	Location Date:	-
Confirmation Number:	7961	Earliest Publication No:	-
Attorney Docket Number:	053694-0131	Earliest Publication Date:	-
Class / Subclass:	424/	Patent Number:	-
First Named Inventor:	Lars Bjorck , Lund, (SE)	Issue Date of Patent:	-

Title of Invention:	Method and treatment
---------------------	----------------------

[Close Window](#)

Transaction History

Date	Transaction Description
03-29-2006	Additional Application Filing Fees
03-29-2006	Information Disclosure Statements
03-29-2006	Drawing Preliminary Amendment
04-27-2006	Sequence disclosure problems
04-11-2006	Cleared by OIPE CSR
04-11-2006	Cleared by OIPE CSR
10-21-2005	Initial Exam Team nn

[**Close Window**](#)

This application is officially maintained in electronic form. To View: Click the desired Document Description. To Download and Print: Check the desired document(s) and click Start Download.

Available Documents

Mail Room Date	Document Description	Document Category	Page Count
11-20-2006	Pre-Exam Formalities Notice	PROSECUTION	3
07-17-2006	Applicant Response to Pre-Exam Formalities Notice	PROSECUTION	2
07-17-2006	Oath or Declaration filed	PROSECUTION	10
03-29-2006	Miscellaneous Internal Document	PROSECUTION	1
03-29-2006	Application Data Sheet	PROSECUTION	5
03-29-2006	Miscellaneous Incoming Letter	PROSECUTION	2
03-29-2006	Oath or Declaration filed	PROSECUTION	16
03-29-2006	Information Disclosure Statement (IDS) Filed	PROSECUTION	4
03-29-2006	Foreign Reference	PRIOR ART	56
03-29-2006	Foreign Reference	PRIOR ART	42
03-29-2006	Foreign Reference	PRIOR ART	94
03-29-2006	Foreign Reference	PRIOR ART	92
03-29-2006	NPL Documents	PRIOR ART	11
03-29-2006	NPL Documents	PRIOR ART	6
03-29-2006	NPL Documents	PRIOR ART	13
03-29-2006	NPL Documents	PRIOR ART	6
03-29-2006	NPL Documents	PRIOR ART	15
03-29-2006	NPL Documents	PRIOR ART	11
03-29-2006	NPL Documents	PRIOR ART	14
03-29-2006	NPL Documents	PRIOR ART	8
03-29-2006	NPL Documents	PRIOR ART	8
03-29-2006	NPL Documents	PRIOR ART	5
03-29-2006	NPL Documents	PRIOR ART	7
03-29-2006	NPL Documents	PRIOR ART	8
03-29-2006	NPL Documents	PRIOR ART	6
03-29-2006	NPL Documents	PRIOR ART	5
03-29-2006	NPL Documents	PRIOR ART	18
03-29-2006	NPL Documents	PRIOR ART	10
10-21-2005	Miscellaneous Internal Document	PROSECUTION	1
10-21-2005	Fee Worksheet (PTO-875)	PROSECUTION	1
10-21-2005	Fee Worksheet (PTO-875)	PROSECUTION	1
10-21-2005	Claims Worksheet (PTO-2022)	PROSECUTION	1
10-21-2005	Transmittal of New Application	PROSECUTION	2
10-21-2005	Specification	PROSECUTION	40
10-21-2005	Claims	PROSECUTION	4
10-21-2005	Abstract	PROSECUTION	1
10-21-2005	Drawings	PROSECUTION	6
10-21-2005	Sequence Listing	PROSECUTION	14
10-21-2005	Miscellaneous Internal Document	PROSECUTION	1
10-21-2005	Fee Worksheet (PTO-875)	PROSECUTION	1
10-21-2005	Preliminary Amendment	PROSECUTION	1
10-21-2005	Claims	PROSECUTION	4
10-21-2005	Applicant Arguments/Remarks Made in an Amendment	PROSECUTION	1
10-21-2005	Certified Copy of Foreign Priority Application	PROSECUTION	69
10-21-2005	Certified Copy of Foreign Priority Application	PROSECUTION	81
10-21-2005	Application Data Sheet	PROSECUTION	5
10-21-2005	Documents submitted with 371 Applications	PROSECUTION	65
10-21-2005	Documents submitted with 371 Applications	PROSECUTION	7

[Close Window](#)

10/553,904	Method and treatment	01-29- 2007::15:15:30
------------	----------------------	--------------------------

Bibliographic Data

Application Number:	10/553,904	Customer Number:	22428
Filing or 371 (c)	-	Status:	Application Undergoing Preexam Processing
Date:			
Application Type:	Utility	Status Date:	11-02-2005
Examiner Name:	-	Location:	ELECTRONIC
Group Art Unit:	1651	Location Date:	-
Confirmation Number:	7961	Earliest Publication No:	-
Attorney Docket Number:	053694-0131	Earliest Publication Date:	-
Class / Subclass:	424/	Patent Number:	-
First Named Inventor:	Lars Bjorck , Lund, (SE)	Issue Date of Patent:	-

Title of Invention:	Method and treatment
---------------------	----------------------

[Close Window](#)

10/553,904	Method and treatment	01-29- 2007::15:15:59
------------	----------------------	--------------------------

Transaction History

Date	Transaction Description
03-29-2006	Additional Application Filing Fees
03-29-2006	Information Disclosure Statements
03-29-2006	Drawing Preliminary Amendment
04-27-2006	Sequence disclosure problems
04-11-2006	Cleared by OIPE CSR
04-11-2006	Cleared by OIPE CSR
10-21-2005	Initial Exam Team nn

[Close Window](#)